<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">74782</article-id><article-id pub-id-type="doi">10.7554/eLife.74782</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-257568"><name><surname>Czaya</surname><given-names>Brian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7888-2432</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251848"><name><surname>Heitman</surname><given-names>Kylie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5345-2727</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251846"><name><surname>Campos</surname><given-names>Isaac</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251839"><name><surname>Yanucil</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251840"><name><surname>Kentrup</surname><given-names>Dominik</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251849"><name><surname>Westbrook</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-257569"><name><surname>Gutierrez</surname><given-names>Orlando</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-257570"><name><surname>Babitt</surname><given-names>Jodie L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-257571"><name><surname>Jung</surname><given-names>Grace</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-257572"><name><surname>Salusky</surname><given-names>Isidro B</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-257573"><name><surname>Hanudel</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-250844"><name><surname>Faul</surname><given-names>Christian</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7512-0977</contrib-id><email>cfaul@uabmc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/008s83205</institution-id><institution>Division of Nephrology and Hypertension, Department of Medicine, The University of Alabama at Birmingham</institution></institution-wrap><addr-line><named-content content-type="city">Birmingham</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>Department of Medicine, David Geffen School of Medicine at UCLA</institution></institution-wrap><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Division of Nephrology, Program in Membrane Biology, Massachusetts General Hospital, Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>Department of Pediatrics, David Geffen School of Medicine at UCLA</institution></institution-wrap><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shoback</surname><given-names>Dolores</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>18</day><month>03</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e74782</elocation-id><history><date date-type="received" iso-8601-date="2021-10-17"><day>17</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-03-17"><day>17</day><month>03</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-10-22"><day>22</day><month>10</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.10.22.465390"/></event></pub-history><permissions><copyright-statement>Â© 2022, Czaya et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Czaya et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-74782-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-74782-figures-v2.pdf"/><abstract><p>Elevations in plasma phosphate concentrations (hyperphosphatemia) occur in chronic kidney disease (CKD), in certain genetic disorders, and following the intake of a phosphate-rich diet. Whether hyperphosphatemia and/or associated changes in metabolic regulators, including elevations of fibroblast growth factor 23 (FGF23) directly contribute to specific complications of CKD is uncertain. Here, we report that similar to patients with CKD, mice with adenine-induced CKD develop inflammation, anemia, and skeletal muscle wasting. These complications are also observed in mice fed high phosphate diet even without CKD. Ablation of pathologic FGF23-FGFR4 signaling did not protect mice on an increased phosphate diet or mice with adenine-induced CKD from these sequelae. However, low phosphate diet ameliorated anemia and skeletal muscle wasting in a genetic mouse model of CKD. Our mechanistic in vitro studies indicate that phosphate elevations induce inflammatory signaling and increase hepcidin expression in hepatocytes, a potential causative link between hyperphosphatemia, anemia, and skeletal muscle dysfunction. Our study suggests that high phosphate intake, as caused by the consumption of processed food, may have harmful effects irrespective of pre-existing kidney injury, supporting not only the clinical utility of treating hyperphosphatemia in CKD patients but also arguing for limiting phosphate intake in healthy individuals.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>chronic kidney disease</kwd><kwd>anemia</kwd><kwd>inflammation</kwd><kwd>hepcidin</kwd><kwd>FGF23</kwd><kwd>hyperphosphatemia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F31-DK-117550</award-id><principal-award-recipient><name><surname>Czaya</surname><given-names>Brian</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F31-DK-115074</award-id><principal-award-recipient><name><surname>Yanucil</surname><given-names>Christopher</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-HL-128714</award-id><principal-award-recipient><name><surname>Faul</surname><given-names>Christian</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008982</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>Alabama Louis Stoke Alliance of Minority Participation (LSAMP) Bridge to the Doctorate (BD)</award-id><principal-award-recipient><name><surname>Campos</surname><given-names>Isaac</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>Research Fellowship</award-id><principal-award-recipient><name><surname>Kentrup</surname><given-names>Dominik</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-HL-145528</award-id><principal-award-recipient><name><surname>Yanucil</surname><given-names>Christopher</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01-DK-125459</award-id><principal-award-recipient><name><surname>Faul</surname><given-names>Christian</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Hyperphosphatemia, by itself and in the context of chronic kidney disease, contributes to iron restrictive anemia by directly targeting the liver and elevating proinflammatory cytokines and hepcidin, which contributes to widespread tissue injury, such as skeletal muscle wasting.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Phosphate (Pi) is an essential mineral nutrient (<xref ref-type="bibr" rid="bib19">Erem and Razzaque, 2018</xref>). Once absorbed and in circulation, Pi is utilized by cells for various structures and functions. Pi metabolism is regulated by a specific set of hormones to maintain physiological Pi concentrations. Fibroblast growth factor 23 (FGF23) is the chief hormone maintaining body Pi balance by promoting renal Pi excretion when Pi load is high (<xref ref-type="bibr" rid="bib24">Fukumoto and Yamashita, 2007</xref>; <xref ref-type="bibr" rid="bib35">Isakova et al., 2011</xref>). Dysregulation of this system causes either low (hypophosphatemia) or high (hyperphosphatemia) serum Pi levels (<xref ref-type="bibr" rid="bib20">Farrow et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">White et al., 2001</xref>; <xref ref-type="bibr" rid="bib78">Wolf, 2012</xref>). Hyperphosphatemic states can result from various conditions, including rare genetic disorders, such as familial tumoral calcinosis (FTC), and acquired diseases, such as chronic kidney disease (CKD), which are more frequent. Moreover, increased consumption of foods and drinks rich in Pi-based additives is expanding in Westernized diets, leading to excess dietary Pi intake (<xref ref-type="bibr" rid="bib9">Carrigan et al., 2014</xref>; <xref ref-type="bibr" rid="bib27">GutiÃ©rrez et al., 2010a</xref>).</p><p>CKD patients have an increased risk of death that is attributable to complications such as inflammation, anemia, and skeletal muscle wasting (<xref ref-type="bibr" rid="bib3">Amdur et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Hoshino et al., 2020</xref>; <xref ref-type="bibr" rid="bib59">Stenvinkel et al., 2016</xref>). The etiology of CKD-associated anemia is multifactorial and includes absolute iron deficiency and functional iron deficiency, with the latter caused by inflammatory cytokines including interleukin-6 (IL6) and interleukin-1Î² (IL1Î²). These inflammatory mediators can directly induce the release of the liver-hormone hepcidin, the master regulator of iron metabolism (<xref ref-type="bibr" rid="bib68">Verga Falzacappa et al., 2007</xref>; <xref ref-type="bibr" rid="bib25">Ganz and Nemeth, 2012</xref>; <xref ref-type="bibr" rid="bib36">Kanamori et al., 2017</xref>). Hepcidin controls the flow of iron into circulation by regulating the iron exporter ferroportin (FPN) (<xref ref-type="bibr" rid="bib49">Nemeth et al., 2004b</xref>). Hepcidin binding occludes FPN (<xref ref-type="bibr" rid="bib4">Aschemeyer et al., 2018</xref>; <xref ref-type="bibr" rid="bib7">BillesbÃ¸lle et al., 2020</xref>) and induces its degradation, thereby restricting iron efflux into the circulation from iron recycling macrophages, a process also known as reticuloendothelial system (RES) blockade, and from duodenal enterocytes responsible for dietary iron absorption. Collectively, these events reduce serum iron levels (hypoferremia), limiting the supply of iron for erythrocyte production (<xref ref-type="bibr" rid="bib48">Nemeth et al., 2004a</xref>).</p><p>Inflammatory cytokines such as IL6 and IL1Î² also act on skeletal muscle and induce muscle wasting, a comorbidity affecting 65% of CKD patients (<xref ref-type="bibr" rid="bib39">Kovesdy et al., 2013</xref>; <xref ref-type="bibr" rid="bib42">Li et al., 2009</xref>; <xref ref-type="bibr" rid="bib83">Zhang et al., 2013</xref>). The loss of protein from muscle is ascribed to protein degradation by the ubiquitinâproteasome system, suppression of protein synthesis and impaired growth of new muscle fibers (<xref ref-type="bibr" rid="bib74">Wang and Mitch, 2014</xref>). As pleotropic activities of IL6 and IL1Î² induce the production of myostatin, a pivotal mediator of skeletal muscle wasting, these actions foster the simultaneous induction of atrophy-related gene programs and reduced cellular responses to progrowth signals, which initiates protein synthesis suppression. Together, inflammation and myostatin advance these CKD-associated comorbidities which reduce the survival and quality of life of CKD patients (<xref ref-type="bibr" rid="bib82">Zhang et al., 2011</xref>).</p><p>A prominent aspect of CKD is altered mineral metabolism, where hyperphosphatemia and excess serum FGF23 are factors associated with inflammation, anemia, and mortality (<xref ref-type="bibr" rid="bib43">Mehta et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Munoz Mendoza et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Navarro-GonzÃ¡lez et al., 2009</xref>; <xref ref-type="bibr" rid="bib65">Tran et al., 2016</xref>). Drugs have been developed to control hyperphosphatemia, but reports show conflicting results about outcomes. Studies of the effects of dietary Pi restriction in animal models are scarce. Dietary interventions to lower Pi intake are challenging because they require long-term behavioral changes made more difficult by the lack of disclosure of Pi content of foods and beverages by the food industry (<xref ref-type="bibr" rid="bib28">GutiÃ©rrez and Wolf, 2010b</xref>).</p><p>All cell types rely on Pi for housekeeping roles, and metabolic Pi uptake is facilitated by three families of sodiumâPi (Na/Pi) cotransporters. Type III Na/Pi cotransporters, PiT-1 and PiT-2, are ubiquitously expressed and mediate cellular Pi homeostasis in all cells (<xref ref-type="bibr" rid="bib40">Lederer and Miyamoto, 2012</xref>). Pathologic Pi accumulation in vasculature is mediated by PiT-1 and PiT-2, loading Pi into vascular smooth muscle cells where it activates signaling networks such as Ras/mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFÎºB) (<xref ref-type="bibr" rid="bib11">Chavkin et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Turner et al., 2020</xref>; <xref ref-type="bibr" rid="bib84">Zhao et al., 2011</xref>). These pathways provide plausible pathomechanisms that support excess Pi as a potential culprit behind the clinical association between hyperphosphatemia and CKD-associated vascular calcification.</p><p>Under physiologic conditions, bone-derived FGF23 targets the kidney to increase Pi excretion by activating its canonical signaling complex, fibroblast growth factor receptor 1 (FGFR1) and co-receptor Klotho (<xref ref-type="bibr" rid="bib17">Czaya and Faul, 2019a</xref>). When FGF23 is in pathological excess, as found in dietary Pi overload or CKD, increased FGF23 targets the heart and liver by activating FGFR4, independently of Klotho (<xref ref-type="bibr" rid="bib21">Faul et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Grabner et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Singh et al., 2016</xref>). This noncanonical mechanism recruits FGFR4 as a pathologic receptor mediating the effects of excess FGF23 to cause cardiac hypertrophy and promote inflammation (<xref ref-type="bibr" rid="bib21">Faul et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Grabner et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Han et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Leifheit-Nestler et al., 2017</xref>; <xref ref-type="bibr" rid="bib58">Singh et al., 2016</xref>; <xref ref-type="bibr" rid="bib79">Xiao et al., 2019</xref>). However, whether excess FGF23 and/or Pi directly contribute to functional iron deficiency or skeletal muscle wasting is unknown, and direct actions of excess Pi on the liver have not been studied to date.</p><p>In this study, we examine whether hyperphosphatemia and/or pathologic FGF23-FGFR4 signaling aggravates functional iron deficiency and skeletal muscle wasting, the common comorbidities in CKD. We expose mice constitutively lacking FGFR4 to hyperphosphatemia in the absence and presence of CKD. To further define the contribution of hyperphosphatemia, we subject Alport mice, a genetic model of progressive CKD, to a low Pi diet treatment. We identify a molecular mechanism in cultured mouse primary hepatocytes that links excess Pi to its actions on inflammation and iron metabolism, as increased inflammatory cytokines promote widespread pathologies and hepcidin production. Our findings reveal additional complications of hyperphosphatemia besides vascular calcification and identify plausible pathomechanisms underlying clinical associations between inflammation, anemia, and skeletal muscle wasting, which could be targeted therapeutically.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>FGF23-FGFR4 signaling does not contribute to functional iron deficiency in adenine-induced CKD</title><p>To examine FGF23 inflammatory actions in vivo, we explored pathologic FGF23-FGFR4 signaling and its role in functional iron deficiency. We subjected wild-type (<italic>Fgfr4<sup>+/+</sup></italic>) and constitutive FGFR4 knockout (<italic>Fgfr4<sup>â/â</sup></italic>) mice to adenine diet to induce CKD. Following adenine diet for 14 weeks, <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice displayed comparable renal dysfunction, as shown by elevations in blood urea nitrogen (BUN) and serum creatinine levels (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). On adenine diet, serum FGF23 and Pi levels significantly increased in both genotypes (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), as expected with marked kidney injury. No significant changes in serum calcium levels were observed between genotypes on adenine (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1A</xref>), despite increased serum Pi levels (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>FGF23-FGFR4 signaling does not contribute to functional iron deficiency in adenine-induced CKD.</title><p>Blood urea nitrogen (BUN), serum creatinine (<bold>A</bold>), serum FGF23 and serum phosphate (Pi) levels (<bold>B</bold>). Quantitative polymerase chain reaction (qPCR) analysis of <italic>Il1b</italic>, <italic>Il6</italic>, <italic>Saa1</italic> (<bold>C, D</bold>) and <italic>Hamp</italic> (<bold>E</bold>) expression levels in liver tissue. (<bold>F</bold>) Complete blood count (CBC) analysis. (<bold>G</bold>) Representative gross pathology of Perlsâ Prussian blue-stained spleen sections (scale bar, 50 Î¼m). Larger magnification is shown in supplementary figure and legends. (<bold>H</bold>) Liver Pi levels. All values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 8â9 mice/group; *p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + control diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + control diet, <sup>$</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + adenine diet) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate median <italic>Fgfr4<sup>+/+</sup></italic> + control diet measurements.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>FGF23-FGFR4 signaling does not contribute to functional iron deficiency in adenine-induced CKD.</title><p>(<bold>A</bold>) Serum calcium analysis from <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, fed either control or adenine diet. (<bold>B</bold>) Hematocrit percentage (HCT%), mean corpuscular hematocrit (MCH), and serum transferrin saturation percentage (TSAT%) analysis in <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, fed either control or adenine diet. (<bold>C</bold>) Representative gross pathology of Perlsâ Prussian blue-stained spleen sections (original magnification, Ã40; scale bar, 20 Î¼m). All values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 8â9 mice/group; *p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + control diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + control diet) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate corresponding median measurements from <italic>Fgfr4<sup>+/+</sup></italic> mice on control diet.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig1-figsupp1-v2.tif"/></fig></fig-group><p>We assessed gene expression of inflammatory cytokines and acute phase proteins in both genotypes in adenine-induced CKD. Unlike in healthy control mice, liver IL1Î² (<italic>Il1b</italic>), IL6 (<italic>Il6</italic>), and serum amyloid A1 (<italic>Saa1</italic>) transcript levels were significantly and similarly elevated (<xref ref-type="fig" rid="fig1">Figure 1C, D</xref>) in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice.</p><p>To identify if FGF23-FGFR4 signaling contributes to functional iron deficiency, we evaluated liver hepcidin (<italic>Hamp</italic>) mRNA and hematological responses. Compared with control mice, <italic>Hamp</italic> transcript levels were significantly and similarly elevated in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice on adenine (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Complete blood count and serum analyses displayed significant reductions in red blood cell (RBC) count, mean corpuscular volume (MCV), hemoglobin, and serum iron levels on adenine diet (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Significant reductions in hematocrit percentage (HCT%), mean corpuscular hematocrit (MCH), and serum transferrin saturation percentage (TSAT%) were also observed (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1B</xref>). Spleen tissue sections stained with Perlsâ Prussian blue revealed profound intracellular iron sequestration, indicating severe RES blockade in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice on adenine (<xref ref-type="fig" rid="fig1">Figure 1G</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1C</xref>). Taken together, our data demonstrate that FGF23-FGFR4 signaling does not affect inflammation, the acute phase response or functional iron deficiency and anemia in adenine-induced CKD.</p></sec><sec id="s2-2"><title>FGF23-FGFR4 signaling does not contribute to hypoferremia following dietary Pi overload</title><p>Excess Pi is a hallmark of CKD, but direct pathologic effects of Pi on tissues other than the vasculature are poorly understood (<xref ref-type="bibr" rid="bib37">Komaba and Fukagawa, 2016</xref>; <xref ref-type="bibr" rid="bib56">Scialla and Wolf, 2014</xref>). To examine if liver Pi deposition is increased in CKD, we analyzed liver Pi levels in adenine-induced mouse CKD model by colorimetric quantification. Hepatic Pi levels were elevated in both <italic>Fgfr4<sup>â/â</sup></italic> and <italic>Fgfr4<sup>+/+</sup></italic> mice following adenine (<xref ref-type="fig" rid="fig1">Figure 1H</xref>) but less so in <italic>Fgfr4<sup>â/â</sup></italic> mice when compared to <italic>Fgfr4<sup>+/+</sup></italic> mice.</p><p>To establish whether excess Pi and/or FGF23 contributes to hypoferremia in the absence of CKD, we exposed <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice to a graded dietary Pi load for 12 weeks. Serum FGF23 levels increased in both genotypes on 2% Pi and 3% Pi diet, in comparison to mice on 0.7% Pi diet (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Despite 2% Pi increasing serum FGF23, serum Pi levels significantly increased only on 3% Pi, in comparison to mice fed 0.7% Pi (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Notably, these serum Pi levels are comparable to the elevated serum Pi levels observed in adenine-induced CKD (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). No significant differences in serum calcium levels were observed between genotypes (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1A</xref>), despite elevated Pi levels (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). No pathologic changes were detected in kidneys regardless of genotype as BUN, serum creatinine, and kidney tissue sections stained with hematoxylin and eosin (H&amp;E) appeared similar to those of mice on 0.7% Pi (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1BâD</xref>). Interstitial fibrosis was not detected in kidneys as shown by Massonâs trichrome staining (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1E</xref>). These data indicate elevations in serum levels of FGF23 and Pi in mice on 2% Pi or 3% Pi diet are consequences of an increasing dietary Pi load and not renal dysfunction.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>FGF23-FGFR4 signaling does not contribute to hypoferremia following dietary Pi overload.</title><p>(<bold>A</bold>) Serum FGF23 and serum Pi levels. (<bold>B, C</bold>) Quantitative polymerase chain reaction (qPCR) analysis of <italic>Il1b</italic>, <italic>Il6</italic>, and <italic>Saa1</italic> expression levels in liver tissue. (<bold>D</bold>) Scatter plots showing correlations between liver Pi and serum Pi levels. (<bold>E</bold>) Scatter plots showing correlations between liver <italic>Hamp</italic> expression and liver Pi levels (a = slopes are significantly different from each other). (<bold>F</bold>) CBC analysis. (<bold>G</bold>) Representative gross pathology of Perlsâ Prussian blue-stained spleen sections (scale bar, 50 Î¼m). Larger magnification is shown in supplementary figure and legends. All values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 8 mice/group; *p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + 0.7% Pi diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + 0.7% Pi diet, <sup>$</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + 2% Pi diet, <sup>@</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + 2% Pi diet, <sup>&amp;</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + 3% Pi diet) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate median <italic>Fgfr4<sup>+/+</sup></italic> + 0.7% Pi diet measurements. Scatter plot shadows indicate 95% confidence interval.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>FGF23-FGFR4 signaling does not contribute to hypoferremia following dietary Pi overload.</title><p>(<bold>A</bold>) Serum calcium analysis from <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, fed either a 0.7% Pi diet or an escalating Pi diet (2% Pi diet or 3% Pi diet). (<bold>B, C</bold>) BUN and serum creatinine analysis from <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, fed either a 0.7% Pi diet or an escalating Pi diet (2% Pi diet or 3% Pi diet). (<bold>D</bold>) Representative gross pathology of H&amp;E-stained kidney sections (original magnification, Ã20; scale bar, 50 Î¼m) from <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, fed either a 0.7% Pi diet or an escalating Pi diet (2% Pi diet or 3% Pi diet). No pathologic changes were detected in sections stained with H&amp;E, as <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice on a 2% Pi or 3% Pi diet display similar results to <italic>Fgfr4<sup>+/+</sup></italic> mice fed a 0.7% Pi diet. (<bold>E</bold>) Representative gross pathology of Massonâs trichrome-stained kidney sections (original magnification, Ã20; scale bar, 50 Î¼m) from <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, fed either a 0.7% Pi diet or an escalating Pi diet (2% Pi diet or 3% Pi diet). No interstitial fibrosis was detected in sections stained with Massonâs trichrome, as <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice on a 2% Pi or 3% Pi diet display similar results to <italic>Fgfr4<sup>+/+</sup></italic> mice fed a 0.7% Pi diet. (<bold>F</bold>) Representative gross pathology of Perlsâ Prussian blue-stained spleen sections (original magnification, Ã40; scale bar, 20 Î¼m). All values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 8 mice/group). Dotted lines indicate corresponding median measurements from <italic>Fgfr4<sup>+/+</sup></italic> mice on 0.7% Pi diet.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 2.</label><caption><title>Liver injury marker and hematological analyses in <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice fed a graded Pi diet.</title><p>(<bold>A, B</bold>) Quantitative polymerase chain reaction (qPCR) analysis of liver tissue shows expression levels of alanine aminotransferase (<italic>Alt1</italic>) and aspartate aminotransferase (<italic>Ast1</italic>) are not significantly elevated in <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, fed either a 2% Pi diet or 3% Pi diet, when compared to <italic>Fgfr4<sup>+/+</sup></italic> mice on a 0.7% Pi diet. (<bold>C</bold>) Hematocrit percentage (HCT%) and mean corpuscular hematocrit (MCH) analysis in <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, fed either a 0.7% Pi diet or an escalating Pi diet (2% Pi diet or 3% Pi diet). All values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 8 mice/group; *p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + 0.7% Pi diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + 0.7% Pi diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + 2% Pi diet, <sup>@</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + 2% Pi diet) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate corresponding median measurements from <italic>Fgfr4<sup>+/+</sup></italic> mice on 0.7% Pi diet.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig2-figsupp2-v2.tif"/></fig></fig-group><p>As a high Pi diet has been reported to exacerbate inflammation and serum FGF23 levels (<xref ref-type="bibr" rid="bib60">Sugihara et al., 2017</xref>; <xref ref-type="bibr" rid="bib61">Takashi et al., 2019</xref>; <xref ref-type="bibr" rid="bib80">Yamada et al., 2014</xref>), we evaluated gene expression of inflammatory cytokines and acute phase proteins. Compared to 0.7% Pi, liver <italic>Il1b</italic>, <italic>Il6</italic>, and <italic>Saa1</italic> transcript levels significantly increased in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice on 3% Pi, although not on 2% Pi diets (<xref ref-type="fig" rid="fig2">Figure 2B, C</xref>). Liver injury was not detected, as no significant elevations in hepatic alanine aminotransferase (<italic>Alt1</italic>) or aspartate aminotransferase (<italic>Ast1</italic>) mRNA levels were found on 3% Pi (<xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2A, B</xref>). These data support the notion that dietary Pi overload induces inflammation, but not via FGF23-FGFR4 signaling.</p><p>To explain these effects of 3% Pi diet and determine if increased tissue Pi deposition is associated with adverse outcomes, we analyzed the relationship between liver and serum Pi levels in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice following a graded dietary Pi load. A positive correlation was detected between hepatic and serum Pi levels in both genotypes, beginning with 2% Pi (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). These results show liver Pi deposits increase following elevations in dietary Pi content.</p><p>Next, we tested if increased liver Pi accumulation affects correlations between liver Pi and liver <italic>Hamp</italic> mRNA levels, as a high Pi diet induces <italic>Hamp</italic> expression (<xref ref-type="bibr" rid="bib46">Nakao et al., 2015</xref>). A positive correlation between liver Pi and liver <italic>Hamp</italic> mRNA levels were detected in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, again only with diets containing 2% or 3% Pi (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). As liver injury was not detected (<xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2A, B</xref>), these data indicate that elevations in liver <italic>Hamp</italic> mRNA are independent of liver injury and may result from Pi-driven inflammation.</p><p>We next explored if increased dietary Pi loading led to changes in hematological responses. Marked reductions in RBC, MCV, hemoglobin, and serum iron levels were detected on 3% Pi and were similar in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). HCT% and MCH were also significantly decreased (<xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2C</xref>). Supporting these findings, spleen tissue sections revealed that both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice showed increased intracellular iron deposits on 3% Pi (<xref ref-type="fig" rid="fig2">Figure 2G</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1F</xref>). Thus, dietary Pi loading causes iron restriction and hypoferremia even in the absence of CKD.</p></sec><sec id="s2-3"><title>Mouse models of hyperphosphatemia exhibit signs of skeletal muscle wasting which are independent of FGF23-FGFR4 signaling</title><p>As inflammation is a known contributor of muscle wasting (<xref ref-type="bibr" rid="bib52">Raj et al., 2008</xref>; <xref ref-type="bibr" rid="bib55">Schaap et al., 2006</xref>; <xref ref-type="bibr" rid="bib69">Verzola et al., 2017</xref>), and since hyperphosphatemia and excess FGF23 are associated with inflammation, we explored whether hyperphosphatemia contributes to skeletal muscle wasting, and if pathologic FGF23-FGFR4 signaling is involved in these effects. We analyzed skeletal muscle from <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice exposed to adenine-induced CKD (<xref ref-type="fig" rid="fig1">Figure 1</xref>) or a graded dietary Pi load (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Examination of skeletal muscle strength indicates that mice on adenine or 3% Pi diet exhibit reduced grip strength in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, in comparison to respective control mice (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). A reduction in gastrocnemius mass was also observed (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Notably, gastrocnemius metallothionein-1 (<italic>Mt1</italic>) transcript levels were significantly elevated in both genotypes following adenine and 3% Pi diets (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1A, B</xref>), indicating that either condition fosters skeletal muscle abnormalities.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mouse models of hyperphosphatemia exhibit signs of skeletal muscle wasting which are independent of FGF23-FGFR4 signaling.</title><p>(<bold>A</bold>) Grip strength. (<bold>B</bold>) Gastrocnemius weight. Quantitative polymerase chain reaction (qPCR) analysis of <italic>Mstn</italic> (<bold>C</bold>), <italic>Murf1</italic> and <italic>Atrogin1</italic> (<bold>D</bold>) expression levels in gastrocnemius tissue. (<bold>E</bold>) Representative gross pathology of H&amp;E-stained gastrocnemius sections (scale bar, 20 Î¼m). All values are mean Â± standard error of the mean (SEM) ((<italic>n</italic> = 8â9 mice/group; *p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + control diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + control diet); (<italic>n</italic> = 8 mice/group; <sup>Î±</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + 0.7% Pi diet, <sup>Î²</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + 0.7% Pi diet, <sup>Î³</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + 2% Pi diet, <sup>Î´</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + 2% Pi diet)) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate median <italic>Fgfr4<sup>+/+</sup></italic> + control diet or <italic>Fgfr4<sup>+/+</sup></italic> + 0.7% Pi diet measurements.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>Models of hyperphosphatemia exhibit signs of skeletal muscle wasting and low Pi feeding in <italic>Col4a3</italic><sup>â/â</sup> (Alport syndrome) mice counteracts muscle dysfunction.</title><p>(<bold>AâC</bold>) Quantitative (qPCR) analysis of gastrocnemius tissue shows expression levels of metallothionein-1 (<italic>Mt1</italic>) are significantly elevated in <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice fed either adenine (<bold>A</bold>) or a 3% Pi diet (<bold>B</bold>). Alport (<italic>Col4a3<sup>â/â</sup></italic>) mice on control diet (0.6% Pi diet) display elevated expression levels of <italic>Mt1</italic> in gastrocnemius tissue, when compared to wild-type (<italic>Col4a3<sup>+/+</sup></italic>) on a 0.6% Pi diet (<bold>C</bold>). A low Pi diet (0.2% Pi) in Alport mice reduces <italic>Mt1</italic> expression levels (<bold>C</bold>). All values are mean Â± standard error of the mean (SEM) ((<italic>n</italic> = 8â9 mice/group; *p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + control diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + control diet); (<italic>n</italic> = 8 mice/group; <sup>Î±</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + 0.7% Pi diet, <sup>Î²</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + 0.7% Pi diet, <sup>Î³</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + 2% Pi diet, <sup>Î´</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + 2% Pi diet); (<italic>n</italic> = 7â9 mice/group; <sup>Îµ</sup>p â¤ 0.05 vs. <italic>Col4a3<sup>+/+</sup></italic> + 0.6% Pi diet, <sup>Ï</sup>p â¤ 0.05 vs. <italic>Col4a3<sup>â/â</sup></italic> + 0.6% Pi diet)) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate corresponding median measurements from <italic>Fgfr4<sup>+/+</sup></italic> mice on control diet (<bold>A</bold>), <italic>Fgfr4<sup>+/+</sup></italic> mice on 0.7% Pi diet (<bold>B</bold>), or <italic>Col4a3<sup>+/+</sup></italic> mice on 0.6% Pi diet (<bold>C</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig3-figsupp1-v2.tif"/></fig></fig-group><p>We next investigated if these muscle deficits resulted from inflammation inducing myostatin and downstream atrophy-related gene programs, as both experimental models display elevated levels of liver <italic>Il1b</italic> and <italic>Il6</italic> (<xref ref-type="fig" rid="fig1">Figures 1C</xref> and <xref ref-type="fig" rid="fig2">2B</xref>). Compared to respective control mice, gastrocnemius myostatin (<italic>Mstn</italic>) transcript levels were significantly elevated in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice following adenine or 3% Pi diet (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Additionally, both genotypes on 2% Pi showed an increased trend in <italic>Mstn</italic> mRNA levels (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). As these findings suggest increased myofibrillar protein degradation, we further analyzed the expression of two specific ubiquitin ligases of muscle-protein breakdown, muscle RING-finger protein 1 (<italic>Murf1</italic>) and <italic>Atrogin-1</italic>. Compared with their respective control mice, gastrocnemius <italic>Murf1</italic> and <italic>Atrogin1</italic> transcript levels were significantly elevated in both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice following adenine and 3% Pi diets (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><p>As elevated myostatin and increased myofibrillar protein degradation are features of skeletal muscle wasting, we assessed if these results prompt a shift toward smaller myofibers. Indeed, gastrocnemius tissue sections stained with H&amp;E from <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, on either adenine or 3% Pi diet, showed smaller muscle fiber size compared with controls (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Taken together, these data suggest skeletal muscle wasting in adenine-induced CKD and hyperphosphatemia does not require FGF23-FGFR4 signaling.</p></sec><sec id="s2-4"><title>Low Pi feeding limits functional iron deficiency in <italic>Col4a3<sup>â/â</sup></italic> (Alport ) mice</title><p>Alport (<italic>Col4a3<sup>â/â</sup></italic>) mice are an established model of progressive CKD which develop hyperphosphatemia with severe inflammation, hypoferremia, and anemia (<xref ref-type="bibr" rid="bib23">Francis et al., 2019</xref>). To test if hyperphosphatemia aggravates these pathologic complications, we exposed <italic>Col4a3<sup>â/â</sup></italic> mice to a low Pi diet treatment (0.2% Pi) for 6 weeks. In comparison to wild-type (<italic>Col4a3<sup>+/+</sup></italic>) mice on normal diet (0.6% Pi), <italic>Col4a3<sup>â/â</sup></italic> mice showed renal dysfunction by increased BUN and serum creatinine levels (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). <italic>Col4a3<sup>â/â</sup></italic> mice on low Pi diet displayed a reduction in both parameters (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), along with reduced pathologic alterations in kidney morphology (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1A</xref>). As compared to wild-type mice, serum levels of FGF23 and Pi significantly increased in <italic>Col4a3<sup>â/â</sup></italic> mice on normal diet (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), but less so in <italic>Col4a3<sup>â/â</sup></italic> mice on low Pi diet (<xref ref-type="fig" rid="fig4">Figure 4B</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Low Pi feeding limits functional iron deficiency in <italic>Col4a3<sup>â/â</sup></italic> (Alport ) mice.</title><p>BUN, serum creatinine (<bold>A</bold>), serum FGF23 and serum Pi levels (<bold>B</bold>). Quantitative polymerase chain reaction (qPCR) analysis of <italic>Il1b</italic>, <italic>Il6</italic>, and <italic>Saa1</italic> (<bold>C, D</bold>) and <italic>Hamp</italic> (<bold>E</bold>) expression levels in liver tissue. (<bold>F</bold>) CBC analysis. (<bold>G</bold>) Representative gross pathology of Perlsâ Prussian blue-stained spleen sections (scale bar, 50 Î¼m). Larger magnification is shown in supplementary figure and legends. (<bold>H</bold>) Liver Pi levels. All values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 7â9 mice/group; *p â¤ 0.05 vs. <italic>Col4a3<sup>+/+</sup></italic> + 0.6% Pi diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Col4a3<sup>â/â</sup></italic> + 0.6% Pi diet) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate median <italic>Col4a3<sup>+/+</sup></italic> + 0.6% Pi diet measurements.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title>Low Pi feeding limits functional iron deficiency in <italic>Col4a3<sup>â/â</sup></italic> (Alport ) mice.</title><p>(<bold>A</bold>) Representative gross pathology of H&amp;E-stained kidney sections (original magnification, Ã20; scale bar, 50 Î¼m) from wild-type (<italic>Col4a3<sup>+/+</sup></italic>) and Alport (<italic>Col4a3<sup>â/â</sup></italic>) mice, fed either control diet (0.6% Pi) or a low Pi diet (0.2% Pi). Pathologic changes were detected in sections stained with H&amp;E from Alport mice fed a 0.6% Pi diet. A 0.2% Pi diet moderately improves this feature in Alport mice. (<bold>B</bold>) Hematocrit percentage (HCT%), mean corpuscular hematocrit (MCH), and serum transferrin saturation percentage (TSAT%) analysis in wild-type (<italic>Col4a3<sup>+/+</sup></italic>) and Alport (<italic>Col4a3<sup>â/â</sup></italic>) mice, fed either control diet (0.6% Pi) or a low Pi diet (0.2% Pi). (<bold>C</bold>) Spleen nonheme iron concentrations in wild-type (<italic>Col4a3<sup>+/+</sup></italic>) and Alport (<italic>Col4a3<sup>â/â</sup></italic>) mice, fed either control diet (0.6% Pi) or a low Pi diet (0.2% Pi). (<bold>D</bold>) Liver nonheme iron concentrations in wild-type (<italic>Col4a3<sup>+/+</sup></italic>) and Alport (<italic>Col4a3<sup>â/â</sup></italic>) mice, fed either control diet (0.6% Pi) or a low Pi diet (0.2% Pi). (<bold>E</bold>) Representative gross pathology of Perlsâ Prussian blue-stained spleen sections (original magnification, Ã40; scale bar, 20 Î¼m). All values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 7â9 mice/group; *p â¤ 0.05 vs. <italic>Col4a3<sup>+/+</sup></italic> + 0.6% Pi diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Col4a3<sup>â/â</sup></italic> + 0.6% Pi diet) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate corresponding median measurements from <italic>Col4a3<sup>+/+</sup></italic> mice on 0.6% Pi diet.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig4-figsupp1-v2.tif"/></fig></fig-group><p>To identify if a low Pi diet affects inflammation or the acute phase response in Alport mice, we assessed gene expression of inflammatory cytokines and acute phase proteins. Compared to wild-type mice on normal diet, liver <italic>Il1b</italic>, <italic>Il6</italic>, and <italic>Saa1</italic> transcript levels were significantly elevated in <italic>Col4a3<sup>â/â</sup></italic> mice but much less elevated on 0.2% Pi (<xref ref-type="fig" rid="fig4">Figure 4C, D</xref>). These data support the notion that excess Pi in Alport mice aggravates inflammation.</p><p>As our results show that a low Pi diet decreases inflammation, we next explored its impact on functional iron deficiency. Compared to wild-type mice on normal diet, liver <italic>Hamp</italic> transcript levels were significantly elevated in <italic>Col4a3<sup>â/â</sup></italic> mice with complete reversal by low Pi diet (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Assessing hematological responses, <italic>Col4a3<sup>â/â</sup></italic> mice on normal diet were anemic, with significant reductions in RBC count, MCV, hemoglobin, and serum iron levels (<xref ref-type="fig" rid="fig4">Figure 4F</xref>), as well as in HCT%, MCH, and TSAT% (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1B</xref>). <italic>Col4a3<sup>â/â</sup></italic> mice on normal diet displayed profound intracellular iron sequestration in spleen (<xref ref-type="fig" rid="fig4">Figure 4G</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1E</xref>), along with excessive spleen and liver nonheme iron levels (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1C, D</xref>). These effects were substantially ameliorated by low Pi diet in <italic>Col4a3<sup>â/â</sup></italic> mice, with improved hematologic parameters and reduced iron deposits in spleen (<xref ref-type="fig" rid="fig4">Figure 4F, G</xref>). Nonheme iron levels in spleen and liver were reduced in <italic>Col4a3<sup>â/â</sup></italic> mice by treatment, indicating increased iron mobilization and decreased iron restriction (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1C, D</xref>). These data indicate that dietary Pi restriction improves hematological responses and alleviates hypoferremia.</p><p>As liver Pi accumulation is increased in adenine-induced CKD (<xref ref-type="fig" rid="fig1">Figure 1H</xref>), we next explored if low Pi diet treatment reduces pathologic liver Pi deposits in progressive CKD. Compared to wild-type mice on normal diet, liver Pi levels were increased in <italic>Col4a3<sup>â/â</sup></italic> mice and were reduced on low Pi diet (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). Taken together, our data demonstrate that Pi restriction as a dietary intervention, in a genetic model of progressive CKD, reduces pathologic Pi accumulation in the liver and alleviates the severity of renal injury and functional iron deficiency.</p></sec><sec id="s2-5"><title>Low Pi feeding counteracts signs of skeletal muscle wasting in <italic>Col4a3<sup>â/â</sup></italic> (Alport ) mice</title><p>To determine if reducing hyperphosphatemia limits skeletal muscle wasting, an important complication of CKD (<xref ref-type="bibr" rid="bib70">Verzola et al., 2019</xref>), we analyzed skeletal muscle from wild-type (<italic>Col4a3<sup>+/+</sup></italic>) and Alport (<italic>Col4a3<sup>â/â</sup></italic>) mice subjected to either a normal diet (0.6% Pi) or a low Pi diet treatment (0.2% Pi) (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Compared to wild-type mice on normal diet, <italic>Col4a3<sup>â/â</sup></italic> mice showed significant reduction in grip strength which was improved by low Pi diet (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Gastrocnemius mass was also reduced in <italic>Col4a3<sup>â/â</sup></italic> mice, and treatment tended to improve muscle weight (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In particular, gastrocnemius <italic>Mt1</italic> transcript levels were significantly elevated in <italic>Col4a3<sup>â/â</sup></italic> mice compared to wild-type mice on normal diet and were reduced by low Pi diet (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1C</xref>). These results suggest that Pi restriction as a dietary intervention may improve skeletal muscle abnormalities in CKD. Furthermore, compared to wild-type mice on normal chow, <italic>Col4a3<sup>â/â</sup></italic> mice displayed significant elevations in gastrocnemius <italic>Mstn</italic> transcript levels which was reduced by treatment (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Additionally, <italic>Col4a3<sup>â/â</sup></italic> mice on normal diet showed increased gastrocnemius <italic>Murf1</italic> and <italic>Atrogin1</italic> transcript levels, which were also reduced by low Pi diet (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). These data support the notion that dietary Pi restriction, as a treatment in <italic>Col4a3<sup>â/â</sup></italic> mice, reduces myostatin synthesis and subsequent atrophy-related gene programs.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Low Pi feeding counteracts signs of skeletal muscle wasting in <italic>Col4a3<sup>â/â</sup></italic> (Alport ) mice.</title><p>(<bold>A</bold>) Grip strength. (<bold>B</bold>) Gastrocnemius weight. Quantitative polymerase chain reaction (qPCR) analysis of <italic>Mstn</italic> (<bold>C</bold>), <italic>Murf1</italic> and <italic>Atrogin1</italic> (<bold>D</bold>) expression levels in gastrocnemius tissue. (<bold>E</bold>) Representative gross pathology of H&amp;E-stained gastrocnemius sections (scale bar, 20 Î¼m). All values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 7â9 mice/group; *p â¤ 0.05 vs. <italic>Col4a3<sup>+/+</sup></italic> + 0.6% Pi diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Col4a3<sup>â/â</sup></italic> + 0.6% Pi diet) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate median <italic>Col4a3<sup>+/+</sup></italic> + 0.6% Pi diet measurements.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig5-v2.tif"/></fig><p>As with adenine-induced CKD mice, or mice fed high phosphate diet, gastrocnemius tissue sections from <italic>Col4a3<sup>â/â</sup></italic> mice showed smaller muscle fiber size compared to wild-type controls (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). However, <italic>Col4a3<sup>â/â</sup></italic> mice fed low Pi diet showed improved muscle fiber size (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Taken together, these data suggest that hyperphosphatemia affects skeletal muscle wasting in Alport mice, possibly by exacerbating systemic inflammatory cytokine concentrations and their catabolic effects on muscle.</p></sec><sec id="s2-6"><title>Pi targets hepatocytes and increases expression of inflammatory cytokines and hepcidin</title><p>Having shown that inflammation, hypoferremia, and muscle wasting induced by high Pi are independent of FGF23-FGFR4 signaling, we tested if Pi directly affects inflammatory cytokine and hepcidin expression in mouse primary hepatocytes.</p><p>We first analyzed the expression profile of the three families of Na/Pi cotransporters (types IâIII). Quantitative polymerase chain reaction (qPCR) analysis detected high levels of <italic>Slc20a1</italic>and <italic>Slc20a2</italic> (encoding for PiT-1 and PiT-2)<italic>,</italic> but not <italic>Slc17a1</italic> and <italic>Slc17a3</italic> (encoding for Npt-1 and Npt-4), or <italic>Slc34a1, Slc34a2</italic> and <italic>Slc34a3</italic> (encoding for NaPi-2a-c) (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1A</xref>). This analysis indicates that type III Na/Pi cotransporters are the predominant Na/Pi family in primary hepatocyte cultures.</p><p>Based on studies demonstrating that high extracellular Pi activates signaling pathways such as MAPK and NFÎºB (<xref ref-type="bibr" rid="bib11">Chavkin et al., 2015</xref>; <xref ref-type="bibr" rid="bib84">Zhao et al., 2011</xref>), we assessed if MAPK, STAT3, and NFÎºB signaling are activated in cultured hepatocytes in response to treatments with FGF23 or graded concentrations of Pi. Treatment with TNFÎ± or IL6 was used as a positive control for activation of these established networks regulating inflammatory gene expression. Immunoblot analysis of ERK1/2, STAT3, and NFÎºB showed that Pi treatments increased phosphorylated NFÎºB levels without changing total NFÎºB expression (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6âsource data 1A</xref>). Increased concentrations of Na<sub>2</sub>SO<sub>4</sub>, a salt generating another anionic species, had no effect on phospho-NFÎºB levels, indicating this response was specific to elevated Pi and not an unspecific response to increased anions. Pi treatment did not affect pERK1/2 or pSTAT3, and FGF23 had no effect on any of the pathways examined.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Pi targets hepatocytes and increases expression of inflammatory cytokines and hepcidin.</title><p>(<bold>A</bold>) Immunoblot analysis of total protein extracts from primary hepatocytes (<italic>n</italic> = 5 independent isolations). Î²-Actin serves as loading control. Quantitative polymerase chain reaction (qPCR) analysis of <italic>Il1b</italic>, <italic>Il6</italic>, <italic>Saa1</italic> (<bold>B, C</bold>), <italic>Hamp</italic> (<bold>D</bold>), and <italic>Slc20a1</italic> (<bold>E</bold>) expression levels in primary hepatocytes; values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 4 independent isolations; *p â¤ 0.05 vs. control [Ctrl]). Dotted lines indicate median Ctrl measurements. (<bold>F</bold>) qPCR analysis of <italic>Slc20a1</italic> expression levels in primary hepatocytes following stimuli, with or without phosphonoformic acid (PFA); values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 6 independent isolations; *p â¤ 0.05 vs. vehicle control [Ctrl], <sup>#</sup>p â¤ 0.05 vs. 1 mM PFA Ctrl). Dotted lines indicate median vehicle Ctrl measurements. (<bold>G</bold>) Immunoblot analysis of total and phosphorylated p65 (NFÎºB) protein levels from primary hepatocytes following stimuli, with or without PFA (<italic>n</italic> = 5 independent isolations). Î²-Actin serves as loading control. (<bold>HâJ</bold>) qPCR analysis of <italic>Il1b</italic>, <italic>Il6</italic>, <italic>Saa1</italic> (<bold>HâI</bold>) and <italic>Hamp</italic> (<bold>J</bold>) expression levels in primary hepatocytes following stimuli, with or without PFA; values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 6 independent isolations; *p â¤ 0.05 vs. vehicle control [Ctrl], <sup>#</sup>p â¤ 0.05 vs. 1 mM PFA Ctrl) where statistical analyses were calculated by one-way analysis of variance (ANOVA; <bold>BâE</bold>) or by two-way ANOVA (<bold>F, HâJ</bold>) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate median vehicle Ctrl measurements.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6âsource data 1.</label><caption><title>Original western blots.</title><p>Original uncropped western blots of the cropped western blots shown in <xref ref-type="fig" rid="fig6">Figure 6A, G</xref>. The molecular weight is indicated on the right in kDa.</p></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-74782-fig6-data1-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6âfigure supplement 1.</label><caption><title>Pi targets hepatocytes and increases expression of inflammatory cytokines and hepcidin.</title><p>(<bold>A</bold>) Quantitative polymerase chain reaction (qPCR) analysis of isolated primary hepatocytes shows absolute transcript expression of all three families of sodium phosphate cotransporters (types I, II, and III). This analysis indicates type III sodium phosphate cotransporters (<italic>Slc20a1</italic> and <italic>Slc20a2</italic>) have the highest expression levels in mouse primary hepatocyte cultures (<italic>n</italic> = 3 independent isolations). (<bold>B</bold>) qPCR analysis of primary hepatocytes shows <italic>Slc20a2</italic> expression levels following inflammatory, dose-dependent Pi or dose-dependent Na<sub>2</sub>SO<sub>4</sub> treatment. No significant elevations were detected following treatments, when compared to control (Ctrl); values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 4 independent isolations). Dotted lines indicate corresponding median measurements from Ctrl.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig6-figsupp1-v2.tif"/></fig></fig-group><p>We next analyzed gene expression by qPCR of inflammatory cytokines and acute phase proteins in isolated hepatocytes treated with increasing concentrations of Pi or Na<sub>2</sub>SO<sub>4</sub> with LPS and IL6 treatments used as positive control. Elevations in <italic>Il1b</italic>, <italic>Il6</italic>, and <italic>Saa1</italic> transcript levels were noted not only following LPS and IL6 but also Pi treatments (<xref ref-type="fig" rid="fig6">Figure 6B, C</xref>). Treatments with Na<sub>2</sub>SO<sub>4</sub> had no effect on gene expression. As inflammation is a known mediator of hepcidin synthesis, we analyzed <italic>Hamp</italic> mRNA levels. LPS, IL6, and Pi treatments all elevated <italic>Hamp</italic> transcript levels when compared to control (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). These data indicate that high extracellular Pi can act on hepatocytes to increase the synthesis of inflammatory cytokines and hepcidin.</p><p>Given that inflammation and NFÎºB signaling regulate PiT-1 expression (<xref ref-type="bibr" rid="bib38">Koumakis et al., 2019</xref>) and primary hepatocytes express <italic>Slc20a1</italic> and <italic>Slc20a2</italic> (<xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1A</xref>), we examined if <italic>Slc20a1</italic> and/or <italic>Slc20a2</italic> mRNA levels were altered following LPS, IL6, or Pi treatment. Expression analysis showed that Pi significantly increased <italic>Slc20a1</italic> transcript levels in a dose-dependent manner but had no effect on <italic>Slc20a2</italic> expression (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6âfigure supplement 1B</xref>). To determine if this result is an action of hepatocytes sensing high extracellular Pi, we cotreated hepatocytes with phosphonoformic acid (PFA), a compound which is reported to inhibit chemisorption of calciumâPi clusters, as aggregate formation is a byproduct of increased extracellular Pi (<xref ref-type="bibr" rid="bib71">Villa-Bellosta et al., 2007</xref>; <xref ref-type="bibr" rid="bib72">Villa-Bellosta and Sorribas, 2009</xref>). In the presence of PFA, Pi-induced <italic>Slc20a1</italic> expression was reduced compared to vehicle-treated control cells (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). Interestingly, PFA also altered the effects of LPS and IL6 on <italic>Slc20a1</italic> expression. To confirm whether inhibiting high extracellular Pi and/or aggregate byproducts disrupts downstream actions of increased extracellular Pi, we cotreated hepatocytes with Pi and PFA, and observed that PFA interfered with Pi-induced effects on phospho-NFÎºB levels without changing total NFÎºB expression (<xref ref-type="fig" rid="fig6">Figure 6G</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6âsource data 1G</xref>).</p><p>Furthermore, when isolated hepatocytes were treated with either LPS, IL6, or Pi in the presence or absence of PFA, the significant elevations in <italic>Il1b</italic>, <italic>Il6</italic>, <italic>Saa1</italic>, and <italic>Hamp</italic> transcript levels following Pi treatments were reversed in the presence of PFA (<xref ref-type="fig" rid="fig6">Figure 6HâJ</xref>). Interestingly, PFA slightly altered the effects of LPS on <italic>Il6</italic> expression and IL6 on <italic>Hamp</italic> expression (<xref ref-type="fig" rid="fig6">Figure 6HâJ</xref>). Taken together, our results indicate that in primary hepatocyte cultures type III Na/Pi cotransporters are predominant, and that increased extracellular Pi activates NFÎºB signaling, increases PiT-1 expression and induces inflammatory cytokine and hepcidin production.</p></sec><sec id="s2-7"><title>Pi induces hepcidin expression via paracrine IL1Î² and IL6 signaling</title><p>Next, we explored if NFÎºB is a necessary mediator for inflammatory cytokine and hepcidin regulation by high extracellular Pi in vitro. We treated mouse primary hepatocytes with either LPS or graded Pi concentrations in the presence or absence of a selective NFÎºB pharmacologic inhibitor, BAY 11-7082 (<xref ref-type="bibr" rid="bib38">Koumakis et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Pierce et al., 1997</xref>). Significant elevations in <italic>Il1b</italic>, <italic>Il6</italic>, and <italic>Hamp</italic> mRNA levels were detected following LPS or Pi treatments, and these were attenuated by BAY 11-7082 (<xref ref-type="fig" rid="fig7">Figure 7A, B</xref>). Similar effects of BAY 11-7082 on <italic>Saa1</italic>, <italic>haptoglobin (Hp</italic>) and <italic>Slc20a1</italic> mRNA expression were also observed, corroborating reports that NFÎºB directly regulates PiT-1 abundance (<xref ref-type="fig" rid="fig7s1">Figure 7âfigure supplement 1AâC</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Pi induces hepcidin expression via paracrine IL1Î² and IL6 signaling.</title><p>Quantitative polymerase chain reaction (qPCR) analysis of <italic>Il1b</italic>, <italic>Il6</italic> (<bold>A</bold>) and <italic>Hamp</italic> (<bold>B</bold>) expression levels in primary hepatocytes following stimuli, with or without BAY 11-7082; values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 4 independent isolations; *p â¤ 0.05 vs. vehicle control [Ctrl], <sup>#</sup>p â¤ 0.05 vs. 20 Î¼M BAY 11-7082 Ctrl). Dotted lines indicate median vehicle Ctrl measurements. (<bold>C</bold>) qPCR analysis of <italic>Hamp</italic> expression levels in primary hepatocytes following stimuli with or without anti-IL1Î², anti-IL6, or both antibodies in combination; values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 4 independent isolations; *p â¤ 0.05 vs. vehicle control [Ctrl], <sup>#</sup>p â¤ 0.05 vs. anti-IL1Î² Ctrl, <sup>$</sup>p â¤ 0.05 vs. anti-IL6 Ctrl, <sup>@</sup>p â¤ 0.05 vs. anti-IL1Î² + anti-IL6 Ctrl) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate median vehicle Ctrl measurements.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7âfigure supplement 1.</label><caption><title>Pi induces hepcidin expression via paracrine IL1Î² and IL6 signaling.</title><p>Quantitative polymerase chain reaction (qPCR) analysis of primary hepatocytes shows expression levels of <italic>Saa1</italic> (<bold>A</bold>), <italic>Hp</italic> (<bold>B</bold>), and <italic>Slc20a1</italic> (<bold>C</bold>) following lipopolysaccharide (LPS) or Pi stimulation, with or without BAY 11-7082; values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 4 independent isolations; *p â¤ 0.05 vs. vehicle control [Ctrl], <sup>#</sup>p â¤ 0.05 vs 20 Î¼M BAY 11-7082 Ctrl). Dotted lines indicate corresponding median measurements from vehicle Ctrl. (<bold>D, E</bold>) qPCR analysis of primary hepatocytes shows <italic>Saa1</italic> and <italic>Hp</italic> expression levels following LPS or Pi stimulation, with or without anti-IL1Î², anti-IL6, or both antibodies in combination; values are mean Â± standard error of the mean (SEM; <italic>n</italic> = 4 independent isolations; *p â¤ 0.05 vs. vehicle control [Ctrl], <sup>#</sup>p â¤ 0.05 vs. anti-IL1Î² Ctrl, <sup>$</sup>p â¤ 0.05 vs. anti-IL6 Ctrl, <sup>@</sup>p â¤ 0.05 vs. anti-IL1Î² + anti-IL6 Ctrl) where statistical analyses were calculated by two-way analysis of variance (ANOVA) followed by Tukeyâs multiple comparison post hoc test. Dotted lines indicate corresponding median measurements from vehicle Ctrl.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig7-figsupp1-v2.tif"/></fig></fig-group><p>As inflammation directly regulates hepcidin, we explored if Pi-induced hepcidin expression is a response resulting from direct or indirect actions of NFÎºB. Testing indirect effects, we cotreated primary hepatocytes with either LPS or graded Pi concentrations in the presence or absence of anti-IL1Î² antibody, anti-IL6 antibody, or both neutralizing antibodies in combination. Expression analysis detected significant elevations in <italic>Hamp</italic> mRNA levels following LPS or Pi treatments and was blunted by addition of either antibody alone or in combination (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). To ensure treatments generated endogenous IL1Î² and IL6 protein, we analyzed <italic>Saa1</italic> and <italic>Hp</italic> mRNA expression, as both genes are regulated by IL1Î² and IL6 (<xref ref-type="bibr" rid="bib85">Zhou et al., 2016</xref>). Compared to vehicle-treated control cells, <italic>Saa1</italic> and <italic>Hp</italic> transcript levels were reduced in the presence of either antibody alone or in combination, following LPS or Pi treatment (<xref ref-type="fig" rid="fig7s1">Figure 7âfigure supplement 1D, E</xref>). Collectively, these results show Pi-mediated hepcidin production in cultured hepatocytes is a result of NFÎºB amplifying PiT-1 expression, which in turn, might intensify high extracellular Pi to augment NFÎºB regulated inflammatory gene programs, prompting the induction of required cytokines IL1Î² and IL6 to mediate hepcidin production.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We report that hyperphosphatemia, either as a result of adenine-induced CKD or dietary Pi excess, increases inflammation to exacerbate anemia and skeletal muscle wasting (<xref ref-type="fig" rid="fig8">Figure 8</xref>). These complications are associated with increased liver Pi levels, which correlated with serum Pi concentrations. Supplying a low Pi diet treatment to Alport mice, a genetic model of CKD, results in beneficial outcomes that reduce functional iron deficiency and skeletal muscle wasting. Furthermore, our mechanistic in vitro studies indicate that Pi elevations induce hepatic production of IL6 and IL1Î² to increase hepcidin expression in hepatocytes, a potential causative link between hyperphosphatemia, anemia, and skeletal muscle dysfunction.</p><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Schematic of the effects of hyperphosphatemia on systemic inflammation, hypoferremia, and skeletal muscle wasting.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-74782-fig8-v2.tif"/></fig><p>Previously, we reported pathologic FGF23-FGFR4 signaling might contribute to excess inflammatory mediators (<xref ref-type="bibr" rid="bib58">Singh et al., 2016</xref>), and we now followed up on the FGF23 inflammatory role in clinically relevant CKD models in vivo. Here, we examined wild-type (<italic>Fgfr4<sup>+/+</sup></italic>) and constitutive FGFR4 knockout (<italic>Fgfr4<sup>â/â</sup></italic>) mice subjected to adenine diet or a graded dietary Pi load. We found that on adenine, both <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice show comparable macroscopic parameters (<xref ref-type="table" rid="table1">Table 1</xref>) and degrees of functional iron deficiency (<xref ref-type="fig" rid="fig1">Figure 1</xref>). These findings coincide with greater levels of liver Pi, which raises the possibility that pathologic Pi deposits, in tissues apart from the vasculature, may contribute to additional complications in CKD (<xref ref-type="bibr" rid="bib37">Komaba and Fukagawa, 2016</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Macroscopic parameters of <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice receiving control and adenine diet.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"><italic>Fgfr4<sup>+/+</sup></italic> + control diet</th><th align="left" valign="bottom"><italic>Fgfr4<sup><bold>â/â</bold></sup></italic> + control diet</th><th align="left" valign="bottom"><italic>Fgfr4<sup>+/+</sup></italic> + adenine diet</th><th align="left" valign="bottom"><italic>Fgfr4<sup><bold>â/â</bold></sup></italic> + adenine diet</th></tr></thead><tbody><tr><td align="left" valign="bottom">Body weight (g)</td><td align="char" char="plusmn" valign="bottom">30.1 Â± 0.9</td><td align="char" char="plusmn" valign="bottom">30.2 Â± 0.3</td><td align="left" valign="bottom">16.8*<sup>#</sup> Â± 0.5</td><td align="left" valign="bottom">17.5*<sup>#</sup> Â± 0.4</td></tr><tr><td align="left" valign="bottom">Liver weight (g)</td><td align="char" char="plusmn" valign="bottom">1.14 Â± 0.05</td><td align="char" char="plusmn" valign="bottom">1.22 Â± 0.08</td><td align="left" valign="bottom">0.74*<sup>#</sup> Â± 0.03</td><td align="left" valign="bottom">0.78*<sup>#</sup> Â± 0.05</td></tr><tr><td align="left" valign="bottom">Spleen weight (mg)</td><td align="char" char="plusmn" valign="bottom">75.0 Â± 2.2</td><td align="char" char="plusmn" valign="bottom">76.0 Â± 1.7</td><td align="left" valign="bottom">53.3*<sup>#</sup> Â± 3.3</td><td align="left" valign="bottom">56.0*<sup>#</sup> Â± 3.2</td></tr><tr><td align="left" valign="bottom">Left kidney weight (mg)</td><td align="char" char="plusmn" valign="bottom">181.8 Â± 8.5</td><td align="char" char="plusmn" valign="bottom">173.2 Â± 8.3</td><td align="left" valign="bottom">122.2*<sup>#</sup> Â± 4.9</td><td align="left" valign="bottom">101.8*<sup>#</sup> Â± 7.2</td></tr><tr><td align="left" valign="bottom">Right kidney weight (mg)</td><td align="char" char="plusmn" valign="bottom">184.7 Â± 10.7</td><td align="char" char="plusmn" valign="bottom">175.2 Â± 8.2</td><td align="left" valign="bottom">124.2*<sup>#</sup> Â± 4.1</td><td align="left" valign="bottom">102.8*<sup>#</sup> Â± 7.7</td></tr></tbody></table><table-wrap-foot><fn><p>Values are expressed as mean Â± standard error of the mean (SEM). Comparison between groups was performed in form of a two-way analysis of variance (ANOVA) followed by a post hoc Tukey test. A level of p &lt; 0.05 was accepted as statistically significant; <italic>N</italic> = 9/group; *p â¤ 0.05 vs. <italic>Fgfr4<sup>+/+</sup></italic> + control diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Fgfr4<sup>â/â</sup></italic> + control diet.</p></fn></table-wrap-foot></table-wrap><p>Clinical reports indicate CKD patients have dysregulated Pi handling (<xref ref-type="bibr" rid="bib10">Chang et al., 2014</xref>; <xref ref-type="bibr" rid="bib34">Isakova et al., 2009</xref>) and together with the consumption of foods and drinks rich in Pi-based additives, such as in a Westernized diet, extrarenal Pi accumulation may occur (<xref ref-type="bibr" rid="bib33">Isakova et al., 2008</xref>). A recent study utilizing animal models supports this postulate, demonstrating that excess Pi leads to depositions into tissues such as the vasculature (<xref ref-type="bibr" rid="bib81">Zelt et al., 2019</xref>). Moreover, a recent report indicates the major source of body Pi removed during hemodialysis in CKD patients, is from cells releasing intracellular Pi (<xref ref-type="bibr" rid="bib12">Chazot et al., 2021</xref>). As the serum Pi compartment represents a small fraction of total body Pi, and the uptake of excess Pi by tissues is recognized as a detrimental trigger, it is important to examine the degree of pathologic Pi accumulation in nonvascular tissue and whether it exacerbates complications in CKD, such as anemia and muscle wasting.</p><p>We employed a graded Pi diet to study the effects of excess Pi on the liver (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Studies show conflicting results toward renal and liver health, following supplementation of a high Pi diet (<xref ref-type="bibr" rid="bib6">Baquerizo et al., 2003</xref>; <xref ref-type="bibr" rid="bib30">Haut et al., 1980</xref>; <xref ref-type="bibr" rid="bib67">Ugrica et al., 2021</xref>). In our study, no significant changes in macroscopic parameters were observed following dietary Pi overload (<xref ref-type="table" rid="table2">Table 2</xref>). Also, no pathologic changes in kidney (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>) or liver were detected (<xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2</xref>). However, mice on a 3% Pi diet exhibit increased liver inflammation and <italic>Hamp</italic> expression, which corroborates previous observation that high dietary Pi influences hepcidin production (<xref ref-type="bibr" rid="bib46">Nakao et al., 2015</xref>). These results coincide with positive correlations between liver Pi and liver <italic>Hamp</italic> mRNA expression, with onset of this correlation preceding significant elevations in serum Pi. Despite these data suggesting that liver Pi influences liver hepcidin production, our finding might indicate that increased extrarenal Pi accumulation provides a reservoir for storing excess Pi until tissue accumulation achieves saturation, in which case the serum Pi compartment then gradually rises, resulting in hyperphosphatemia. Furthermore, our data suggest that prolonged exposure to Pi, if not maintained in adequate quantities, might trigger pathologic outcomes, as mice on 3% Pi show a noticeable degree of hypoferremia. None of the observed effects of the high Pi diet were mediated by FGFR4, as <italic>Fgfr4<sup>â/â</sup></italic> mice were comparable to wild-type mice in all the parameters measured. However, this work cannot exclude the potential of alternative FGFR isoforms which might mediate the effects of excess FGF23 toward functional iron deficiency following either adenine or 3% Pi diet, as a previous report exhibits the utilization of a single intraperitoneal injection of FGF23 blocking peptide was sufficient to rescue anemia (<xref ref-type="bibr" rid="bib2">Agoro et al., 2018</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Macroscopic parameters of <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice receiving a graded dietary Pi load.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"><italic>Fgfr4<sup>+/+</sup></italic> + 0.7% Pi diet</th><th align="left" valign="bottom"><italic>Fgfr4<sup><bold>â/â</bold></sup></italic> + 0.7% Pi diet</th><th align="left" valign="bottom"><italic>Fgfr4<sup>+/+</sup></italic> + 2% Pi diet</th><th align="left" valign="bottom"><italic>Fgfr4<sup><bold>â/â</bold></sup></italic> + 2% Pi diet</th><th align="left" valign="bottom"><italic>Fgfr4<sup>+/+</sup></italic> + 3% Pi diet</th><th align="left" valign="bottom"><italic>Fgfr4<sup><bold>â/â</bold></sup></italic> + 3% Pi diet</th></tr></thead><tbody><tr><td align="left" valign="bottom">Body weight (g)</td><td align="char" char="plusmn" valign="bottom">32.0 Â± 1.0</td><td align="char" char="plusmn" valign="bottom">31.9 Â± 1.0</td><td align="char" char="plusmn" valign="bottom">30.3 Â± 0.9</td><td align="char" char="plusmn" valign="bottom">31.6 Â± 0.9</td><td align="char" char="plusmn" valign="bottom">29.5 Â± 0.3</td><td align="char" char="plusmn" valign="bottom">29.5 Â± 0.4</td></tr><tr><td align="left" valign="bottom">Liver weight (g)</td><td align="char" char="plusmn" valign="bottom">1.17 Â± 0.04</td><td align="char" char="plusmn" valign="bottom">1.15 Â± 0.05</td><td align="char" char="plusmn" valign="bottom">1.24 Â± 0.03</td><td align="char" char="plusmn" valign="bottom">1.20 Â± 0.05</td><td align="char" char="plusmn" valign="bottom">1.23 Â± 0.5</td><td align="char" char="plusmn" valign="bottom">1.19 Â± 0.4</td></tr><tr><td align="left" valign="bottom">Spleen weight (mg)</td><td align="char" char="plusmn" valign="bottom">76.3 Â± 2.4</td><td align="char" char="plusmn" valign="bottom">68.3 Â± 1.7</td><td align="char" char="plusmn" valign="bottom">77.0 Â± 2.8</td><td align="char" char="plusmn" valign="bottom">76.6 Â± 2.8</td><td align="char" char="plusmn" valign="bottom">76.6 Â± 2.1</td><td align="char" char="plusmn" valign="bottom">74.0 Â± 1.7</td></tr><tr><td align="left" valign="bottom">Left kidney weight (mg)</td><td align="char" char="plusmn" valign="bottom">146.5 Â± 4.7</td><td align="char" char="plusmn" valign="bottom">143.6 Â± 4.5</td><td align="char" char="plusmn" valign="bottom">156.0 Â± 2.9</td><td align="char" char="plusmn" valign="bottom">152.6 Â± 3.4</td><td align="char" char="plusmn" valign="bottom">153.4 Â± 4.1</td><td align="char" char="plusmn" valign="bottom">152.9 Â± 3.7</td></tr><tr><td align="left" valign="bottom">Right kidney weight (mg)</td><td align="char" char="plusmn" valign="bottom">149.0 Â± 3.8</td><td align="char" char="plusmn" valign="bottom">151.5 Â± 3.7</td><td align="char" char="plusmn" valign="bottom">152.9 Â± 3.2</td><td align="char" char="plusmn" valign="bottom">145.6 Â± 3.5</td><td align="char" char="plusmn" valign="bottom">152.5 Â± 2.5</td><td align="char" char="plusmn" valign="bottom">149.6 Â± 3.9</td></tr></tbody></table><table-wrap-foot><fn><p>Values are expressed as mean Â± standard error of the mean (SEM). Comparison between groups was performed in form of a two-way analysis of variance (ANOVA) followed by a post hoc Tukey test. No level of statistical significance was accepted between groups; <italic>N</italic> = 8/group.</p></fn></table-wrap-foot></table-wrap><p>Excess dietary Pi was shown to directly exacerbate intestinal inflammation in a model of experimental colitis (<xref ref-type="bibr" rid="bib60">Sugihara et al., 2017</xref>) and that reducing dietary Pi provides beneficial outcomes toward systemic inflammation, accelerated aging, and survival, as demonstrated in a model of senescence (<xref ref-type="bibr" rid="bib44">Morishita et al., 2001</xref>). We likewise observed increased inflammation in our hyperphosphatemic mouse models. Inflammatory cytokines can directly target skeletal muscle cells to induce muscle wasting by increasing myostatin production (<xref ref-type="bibr" rid="bib83">Zhang et al., 2013</xref>), which both together, enhances protein degradation and reduces protein synthesis, as CKD illustrates catabolic conditions which are attributable to the vicious cycle generated between mineral dyshomeostasis and inflammation (<xref ref-type="bibr" rid="bib18">Czaya and Faul, 2019b</xref>). We indeed observed skeletal muscle wasting in adenine-induced CKD, high phosphate diet, and genetic model of CKD. Ablation of FGFR4 in mice did not improve skeletal muscle function following adenine or 3% Pi diets, suggesting hyperphosphatemia rather than pathologic FGF23-FGFR4 signaling might be the cause of skeletal muscle abnormalities (<xref ref-type="fig" rid="fig3">Figure 3</xref>). This hypothesis is supported by reports demonstrating excess Pi influences skeletal muscle dysfunction (<xref ref-type="bibr" rid="bib1">Acevedo et al., 2016</xref>; <xref ref-type="bibr" rid="bib13">Chen et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Chung et al., 2020</xref>), although it is possible additional FGFR isoforms directly promote skeletal muscle wasting due to excess FGF23 following adenine or high Pi diet. However, a recent report suggests that FGF23 does not directly affect skeletal muscle dysfunction (<xref ref-type="bibr" rid="bib5">Avin et al., 2018</xref>).</p><p>To assess whether reducing hyperphosphatemia can improve inflammation, anemia, and skeletal muscle wasting, we exposed Alport mice, a genetic model of progressive CKD, to a low Pi diet treatment. Indeed, despite severe elevations in serum FGF23, dietary Pi restriction limited functional iron deficiency (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Our data also show liver Pi levels were reduced in Alport mice following low Pi diet treatment, in comparison to Alport mice on normal diet. These findings provide strong evidence that hyperphosphatemia, specifically pathologic liver Pi accumulation, rather than pathologic FGF23-FGFR4 signaling, might exacerbate inflammation and hypoferremia. Skeletal muscle function and mass were also improved by a low Pi diet in Alport mice, along with decreased expression of muscle myostatin and atrophy-related gene programs, culminating in larger myofiber size. These findings suggest the contribution of hyperphosphatemia to skeletal muscle wasting may result from an indirect mechanism that regulates inflammatory cytokines and their pleotropic activities, such as increased liver-derived IL1Î² and IL6, which might increase overall systemic levels that effectively target skeletal muscle. Despite this postulate, further work will be needed to determine if high extracellular Pi directly targets skeletal muscle cells to affect muscle function. Nonetheless, these data add to the growing list of adverse outcomes of Pi toxicity such as gingivitis, accelerated aging, vascular calcification and tumorigenesis (<xref ref-type="bibr" rid="bib19">Erem and Razzaque, 2018</xref>). Furthermore, Alport mice on low Pi diet treatment displayed a reduced degree of pathologic kidney function, alterations in kidney morphology, and macroscopic parameters (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>, <xref ref-type="table" rid="table3">Table 3</xref>). Thus, we cannot exclude that these beneficial outcomes in Alport mice observed on treatment may be a repercussion of slightly improved kidney function, as a recent report demonstrates elevated Pi concentrations directly affect proximal tubular function (<xref ref-type="bibr" rid="bib57">Shiizaki et al., 2021</xref>).</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Macroscopic parameters of Alport mice receiving either a 0.6% Pi diet or 0.2% Pi diet.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"><italic>Col4a3<sup>+/+</sup></italic> + 0.6% Pi diet</th><th align="left" valign="bottom"><italic>Col4a3<sup>â/â</sup></italic> + 0.6% Pi diet</th><th align="left" valign="bottom"><italic>Col4a3<sup>â/â</sup></italic> + 0.2% Pi diet</th></tr></thead><tbody><tr><td align="left" valign="bottom">Body weight (g)</td><td align="char" char="plusmn" valign="bottom">26.3 Â± 0.6</td><td align="char" char="plusmn" valign="bottom">16.3* Â± 0.6</td><td align="left" valign="bottom">22.2*<sup>#</sup> Â± 0.6</td></tr><tr><td align="left" valign="bottom">Liver weight (g)</td><td align="char" char="plusmn" valign="bottom">1.03 Â± 0.04</td><td align="char" char="plusmn" valign="bottom">0.68* Â± 0.03</td><td align="left" valign="bottom">0.90<sup>#</sup> Â± 0.03</td></tr><tr><td align="left" valign="bottom">Spleen weight (mg)</td><td align="char" char="plusmn" valign="bottom">72.2 Â± 2.3</td><td align="char" char="plusmn" valign="bottom">56.6* Â± 2.4</td><td align="char" char="plusmn" valign="bottom">65.9 Â± 2.1</td></tr><tr><td align="left" valign="bottom">Left kidney weight (mg)</td><td align="char" char="plusmn" valign="bottom">145.3 Â± 1.6</td><td align="char" char="plusmn" valign="bottom">124.1* Â± 2.6</td><td align="char" char="plusmn" valign="bottom">130.1* Â± 2.1</td></tr><tr><td align="left" valign="bottom">Right kidney weight (mg)</td><td align="char" char="plusmn" valign="bottom">147.4 Â± 1.6</td><td align="char" char="plusmn" valign="bottom">123.0* Â± 3.4</td><td align="char" char="plusmn" valign="bottom">133.6* Â± 3.1</td></tr></tbody></table><table-wrap-foot><fn><p>Values are expressed as mean Â± standard error of the mean (SEM). Comparison between groups was performed in form of a two-way analysis of variance (ANOVA) followed by a post hoc Tukey test. A level of p &lt; 0.05 was accepted as statistically significant; <italic>N</italic> = 7â9/group; *p â¤ 0.05 vs. <italic>Col4a3<sup>+/+</sup></italic> + 0.6% Pi diet, <sup>#</sup>p â¤ 0.05 vs. <italic>Col4a3<sup>â/â</sup></italic> + 0.6% Pi diet.</p></fn></table-wrap-foot></table-wrap><p>Importantly, we identify a molecular mechanism that potentially links hyperphosphatemia to anemia and skeletal muscle dysfunction. Utilizing mouse primary hepatocytes, we demonstrate high extracellular Pi activates NFÎºB signaling and leads to subsequent inflammatory cytokine and hepcidin production (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Employing PFA, a compound reported to reduce calciumâPi deposition and cluster formation, as aggregates are a byproduct of increased extracellular Pi (<xref ref-type="bibr" rid="bib71">Villa-Bellosta et al., 2007</xref>; <xref ref-type="bibr" rid="bib72">Villa-Bellosta and Sorribas, 2009</xref>), we confirm NFÎºB activation is a direct action of Pi targeting hepatocytes, which prompts subsequent <italic>Slc20a1</italic> mRNA expression, as observed from our BAY 11-7082 findings. This high extracellular Pi-NFÎºB signaling axis is observed in other reservoirs such as vascular smooth muscle cells and ex vivo kidney slices, as well as adjuncts the rewiring of various signaling networks that control cellular homeostasis following excessive Pi exposure (<xref ref-type="bibr" rid="bib31">He et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">RodrÃ­guez-Ortiz et al., 2020</xref>; <xref ref-type="bibr" rid="bib73">Voelkl et al., 2018</xref>; <xref ref-type="bibr" rid="bib84">Zhao et al., 2011</xref>). Although this reaffirms NFÎºB directly influences PiT-1 levels (<xref ref-type="bibr" rid="bib38">Koumakis et al., 2019</xref>), it does not identify if our observations are dependent or independent of Pi translocation, as extracellular Pi might associate with various PiT-1 extracellular regions to influence PiT-1/PiT-1 homodimerization, PiT-1/PiT-2 heterodimerization or a conformational change in PiT-1 to initiate the activation of selected binding partners which mediate downstream signaling events (<xref ref-type="bibr" rid="bib8">Bon et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">Forand et al., 2016</xref>). In addition to the amplified hepatic PiT-1 abundance and recognition of NFÎºB as a necessary mediator of high extracellular Pi in hepatocytes, we show that the effect of Pi on hepcidin requires the indirect actions of NFÎºB and biological activities of endogenous IL1Î² and IL6 proteins secreted by hepatocytes, as elucidated by our cell-based neutralization assay of these targeted cytokines (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Based on these findings, we speculate increased liver Pi deposits might underlie a clinical association between elevated body Pi and inflammation, where the prolonged duration of tissue accumulation permits Pi in the liver to directly target hepatocytes to induce inflammatory gene programs and hepcidin expression, contributing to hypoferremia. This could explain associations of inflammation and anemia in FTC patients, in addition to patients with and without CKD, before they exhibit hyperphosphatemia (<xref ref-type="bibr" rid="bib53">Ramnitz et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Tran et al., 2016</xref>; <xref ref-type="bibr" rid="bib77">Wojcicki, 2013</xref>).</p><p>Our study has some limitations. Although we confirm hyperphosphatemia affects specific complications, our study does not specifically address the actions of certain aggregate byproducts formed by increased extracellular Pi. Nonetheless, this principal emphasis on elevations in plasma Pi concentrations will ultimately impact the formation of byproducts. Notably, the identification of the specific Pi sensor which mediates our observed hepatic Pi actions are not definite and remains to be defined with our ongoing studies. Moreover, our study does not address the specific actions of hyperphosphatemia on bone metabolism. As bone is a reservoir of extracellular Pi, potential alterations in bone health could relay a crosstalk between bone, liver, and/or skeletal muscle, which might contribute to our reported observations.</p><p>In summary, we investigated whether hyperphosphatemia and/or pathologic FGF23-FGFR4 signaling aggravates inflammation, anemia, and skeletal muscle wasting. We establish hyperphosphatemia, as found in dietary Pi overload or in CKD, is a detrimental trigger which activates hepatic NFÎºB signaling to stimulate an inflammatory response, which in turn, exacerbates hypoferremia and widespread complications such as skeletal muscle wasting. Notably, these findings are independent of pathologic FGF23-FGFR4 signaling. Clinical studies have demonstrated conflicting outcomes with traditional Pi binders in individuals with nondialysis-dependent CKD, but modern Pi binders, such as ferric citrate, demonstrate greater efficacy (<xref ref-type="bibr" rid="bib23">Francis et al., 2019</xref>; <xref ref-type="bibr" rid="bib64">Toussaint et al., 2020</xref>), and are being evaluated for their effect on CKD comorbidities. Furthermore, reports assessing dietary Pi restriction in animal models are scarce. Our current experimental data suggest hyperphosphatemia, in itself, is pathologic and demands further attention for alternative strategies to resolve current ineffective approaches. Treatments, such as pharmacologic inhibition of type II Na/Pi cotransporters, hold potential for therapeutic actions (<xref ref-type="bibr" rid="bib15">Clerin et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Thomas et al., 2019</xref>) but do not aim at altered mineral metabolism. Using in vitro studies and complementary animal models, we provide insights regarding the interconnection between altered mineral metabolism and common complications. Dietary Pi restriction might alleviate these sequelae, if sustained effectively as a clinical treatment. By elucidating direct inflammatory actions of high extracellular Pi on hepatocytes, we expose additional adverse outcomes of hyperphosphatemia, besides vascular calcification. These findings may yield new targets for therapeutic development, with emphasis on hepatic Pi actions. Moreover, as studies indicate anti-FGFR4 therapy may be beneficial toward cardiomyopathy (<xref ref-type="bibr" rid="bib26">Grabner et al., 2015</xref>), our data suggest these same beneficial outcomes for inflammation, anemia, and skeletal muscle wasting would not apply. Altogether, our study features a possibility to improve CKD patient survival and specific rare genetic disorders, such as FTC, by limiting excess body Pi.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>; 129/SvJ)</td><td align="left" valign="bottom"><italic>Col4a3<sup>tm1Dec</sup></italic></td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom">Stock No. 000691</td><td align="left" valign="bottom">Referred to as <italic>Col4a3<sup>â/â</sup></italic></td></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>; C57Bl/6)</td><td align="left" valign="bottom">Global FGFR4 knockout</td><td align="left" valign="bottom">Gift from Dr. Chu-Xia Deng, NIDDK, Bethesda, USA</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib75">Weinstein et al., 1998</xref>, 125, 3615-23</td><td align="left" valign="bottom">Referred to as <italic>Fgfr4<sup>â/â</sup></italic></td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IL6 (rat monoclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">MP5-20F3</td><td align="left" valign="bottom">For cell culture treatment (6 Î¼g/ml)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IL1Î² (goat polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">AF-401-NA</td><td align="left" valign="bottom">For cell culture treatment (6 Î¼g/ml)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ERK1/2 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="char" char="." valign="bottom">4695</td><td align="left" valign="bottom">For WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">STAT3 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="char" char="." valign="bottom">4904</td><td align="left" valign="bottom">For WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">NFkB (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="char" char="." valign="bottom">8242</td><td align="left" valign="bottom">For WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Î²-Actin (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="char" char="." valign="bottom">4970</td><td align="left" valign="bottom">For WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phosphorylated ERK1/2 (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="char" char="." valign="bottom">9101</td><td align="left" valign="bottom">For WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phosphorylated STAT3 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="char" char="." valign="bottom">9145</td><td align="left" valign="bottom">For WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Phosphorylated NFÎºB (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="char" char="." valign="bottom">3033</td><td align="left" valign="bottom">For WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Mouse IgG, HRP conjugate (goat monoclonal)</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">W4021</td><td align="left" valign="bottom">For WB (1:2500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit IgG, HRP conjugate (goat monoclonal)</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">W4011</td><td align="left" valign="bottom">For WB (1:2500)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">FGF23; mouse</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="char" char="hyphen" valign="bottom">2629-FG</td><td align="left" valign="bottom">For cell culture treatment (25 ng/ml)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">TNFÎ±; mouse</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="char" char="hyphen" valign="bottom">410-MT</td><td align="left" valign="bottom">For cell culture treatment (100 ng/ml)</td></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">IL6; mouse</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="char" char="." valign="bottom">406 ML</td><td align="left" valign="bottom">For cell culture treatment (50 ng/ml)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Colorimetric Pi assay</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Ab65622</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Colorimetric iron assay</td><td align="left" valign="bottom">Sekisui</td><td align="char" char="ndash" valign="bottom">157-30</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Intact FGF23 ELISA (mouse)</td><td align="left" valign="bottom">Quidel</td><td align="char" char="ndash" valign="bottom">60-6800</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Percoll gradient solution</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P1644</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Plus Mini kit</td><td align="left" valign="bottom">Qiagen</td><td align="char" char="." valign="bottom">74,136</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Plus Universal Mini kit</td><td align="left" valign="bottom">Qiagen</td><td align="char" char="." valign="bottom">73,404</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">iScript Reverse Transcriptase Supermix</td><td align="left" valign="bottom">BioRad</td><td align="char" char="." valign="bottom">1708840</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SSoAdvanced Universal SYBR Green Supermix</td><td align="left" valign="bottom">BioRad</td><td align="char" char="ndash" valign="bottom">172-5272</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA Protein Assay</td><td align="left" valign="bottom">Thermo Fisher</td><td align="char" char="." valign="bottom">23,225</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Lipopolysaccharide (LPS) from <italic>E. coli</italic> serotype 0111:B4; endotoxin agent</td><td align="left" valign="bottom">Invivogen</td><td align="left" valign="bottom">Tlrl-3pelps</td><td align="left" valign="bottom">For cell culture treatment (100 ng/ml)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium phosphate dibasic anhydrous</td><td align="left" valign="bottom">Fisher</td><td align="left" valign="bottom">BP332-500</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium phosphate monobasic anhydrous</td><td align="left" valign="bottom">Fisher</td><td align="left" valign="bottom">BP329-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Sodium Sulfate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="char" char="." valign="bottom">239,313</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphonoformic acid (PFA)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">P6801</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BAY 11-7082</td><td align="left" valign="bottom">Selleckhem</td><td align="left" valign="bottom">S2913</td><td align="left" valign="bottom">For cell culture treatment (20 Î¼M)</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">0.2% adenine diet</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom">TD.140290</td><td align="left" valign="bottom">Diet for mice</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">0.15% adenine diet</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom">TD.170304</td><td align="left" valign="bottom">Diet for mice</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Adenine control diet</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom">TD.170303</td><td align="left" valign="bottom">Diet for mice</td></tr><tr><td align="left" valign="bottom">Other</td><td align="char" char="." valign="bottom">0.7% Pi diet</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom">TD.180287</td><td align="left" valign="bottom">Diet for mice</td></tr><tr><td align="left" valign="bottom">Other</td><td align="char" char="." valign="bottom">2% Pi diet</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom">TD.08020</td><td align="left" valign="bottom">Diet for mice</td></tr><tr><td align="left" valign="bottom">Other</td><td align="char" char="." valign="bottom">3% Pi diet</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom">TD.180286</td><td align="left" valign="bottom">Diet for mice</td></tr><tr><td align="left" valign="bottom">Other</td><td align="char" char="." valign="bottom">0.6% Pi diet</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom">TD.200407</td><td align="left" valign="bottom">Diet for mice</td></tr><tr><td align="left" valign="bottom">Other</td><td align="char" char="." valign="bottom">0.2% Pi diet</td><td align="left" valign="bottom">Envigo</td><td align="left" valign="bottom">TD.200406</td><td align="left" valign="bottom">Diet for mice</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Materials</title><p>Recombinant proteins used are mouse FGF23 (2629-FG, R&amp;D Systems), mouse TNFÎ± (410-MT, R&amp;D Systems), and mouse IL6 (406 ML, R&amp;D Systems). This FGF23 peptide contains an arginine to glutamine amino acid substitution at position 179 which yields it resistant to furin protease-mediated degradation, thus prolonging its half-life. Lipopolysaccharide (LPS) from <italic>E. coli</italic> serotype 0111:B4 (tlrl-3pelps, Invivogen) was used as endotoxin. Sodium phosphate dibasic anhydrous (Na<sub>2</sub>HPO<sub>4</sub>) (BP332-500, Fisher Scientific) and sodium phosphate monobasic anhydrous (NaH<sub>2</sub>PO<sub>4</sub>) (BP329-1, Fisher Scientific) were used to prepare a 1 M stock sodium phosphate buffer solution containing 500 mM Na<sub>2</sub>HPO<sub>4</sub> and 500 mM NaH<sub>2</sub>PO<sub>4</sub> at an adjusted pH of 7.4. Sodium sulfate (Na<sub>2</sub>SO<sub>4</sub>) (239313, Sigma-Aldrich) was used to prepare a 1 M stock sodium sulfate buffer solution at an adjusted pH of 7.4. PFA (P6801, Sigma-Aldrich) and BAY 11-7082 (S2913, Selleckchem) were used as agents to elucidate underlying signal transduction mechanisms. Anti-IL6 (MP5-20F3, R&amp;D Systems) and anti-IL1Î² (AF-401-NA, R&amp;D Systems) were used as antibodies in a cell-based assay to neutralize the biological activity of targeted cytokines.</p></sec><sec id="s4-2"><title>Mice</title><p>Animal studies were performed in the conformity with applicable laws and guidelines and were approved by the Animal Research Committee at the University of Alabama Birmingham School of Medicine (UAB). Studies were performed using male mice and were maintained on a NIH 31 rodent diet (Harlan Teklad) and fed ad libitum, unless otherwise indicated. Constitutive FGF Receptor four null (<italic>Fgfr4<sup>â/â</sup></italic>) mice (<xref ref-type="bibr" rid="bib75">Weinstein et al., 1998</xref>) were maintained on a C57BL/6 background. Constitutive <italic>Col4a3<sup>â/â</sup></italic> null (Alport) mice (<xref ref-type="bibr" rid="bib16">Cosgrove et al., 1996</xref>) were maintained on a mixed Sv129/C57BL/6 background. Both mouse models were housed in our UAB rodent facility, in a heterozygous breeding state.</p><p>For experiments exploring the contribution of pathologic FGF23-FGFR4 signaling to CKD-associated pathologies, 10- to 14-week-old <italic>Fgfr4<sup>â/â</sup></italic> mice and corresponding wild-type littermates were placed on a customized diet containing 0.2% adenine (TD.140290, Envigo) for 6 weeks, switched to a customized diet containing 0.15% adenine (TD.170304, Envigo) for 2 weeks and transitioned back to the customized 0.2% adenine diet for an additional 6 weeks. Wild-type littermates placed on a customized control diet (TD.170303, Envigo) served as controls. All experimental groups were permitted a 1-week dietary acclimation period, using the customized control diet. After dietary acclimation, mice were unbiasedly assigned to either the customized control diet or customized adenine diet. After the 14-week duration, mice were euthanized under 2.5% isoflurane anesthesia and samples were prepared as described below. This experimental timeline is in accordance with previous studies (<xref ref-type="bibr" rid="bib50">Noonan et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Taylor et al., 2019</xref>). Adenine is known to induce kidney tubule-interstitial damage and is considered a dietary model of CKD.</p><p>For experiments testing the contribution of pathologic FGF23-FGFR4 signaling to systemic effects of a graded dietary phosphate load, 10- to 14-week-old <italic>Fgfr4<sup>â/â</sup></italic> mice and corresponding wild-type littermates were unbiasedly assigned and fed a customized 0.7% phosphate diet (TD.180287, Envigo), a customized 2.0% phosphate diet (TD.08020, Envigo) or a customized 3.0% phosphate diet (TD.180286, Envigo) for 12 weeks. Wild-type littermates placed on the customized 0.7% phosphate diet served as controls. At end of the experimental period, mice were euthanized under 2.5% isoflurane anesthesia and samples were prepared as described below.</p><p>For experiments investigating the contribution of hyperphosphatemia to CKD-associated pathologies, 4-week-old Alport mice and corresponding wild-type littermates were unbiasedly assigned and fed a customized 0.6% phosphate diet (TD.200407, Envigo) or a customized 0.2% phosphate diet (TD.200406, Envigo) as treatment for 6 weeks. Constitutive <italic>Col4a3<sup>â/â</sup></italic> null mice are considered a genetic model of Alport syndrome and progressive CKD. When maintained on a mixed Sv129/C57BL/6 background, Alport mice die at 10 weeks of age due to rapid renal injury. Wild-type littermates placed on the customized 0.6% phosphate diet served as controls. At 10 weeks of age, mice were euthanized under 2.5% isoflurane anesthesia and samples were prepared as described below. A detailed description of diet compositions is indicated in <xref ref-type="table" rid="table4">Table 4</xref>; <xref ref-type="table" rid="table5">Table 5</xref>; <xref ref-type="table" rid="table6">Table 6</xref>. All experimental group numbers were predetermined on the basis of experience from previous publications. Investigators were not blinded to mouse genotypes.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Composition of control and adenine diets.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Diet</th><th align="left" valign="bottom">Adenine(g/kg)</th><th align="left" valign="bottom">Available Pi (%)</th><th align="left" valign="bottom">Total Ca (%)</th><th align="left" valign="bottom">Protein source</th><th align="left" valign="bottom">Energy source</th><th align="left" valign="bottom">Pi source</th></tr></thead><tbody><tr><td align="left" valign="bottom">TD.170303(control diet)</td><td align="char" char="." valign="bottom">0</td><td align="char" char="." valign="bottom">0.9</td><td align="char" char="." valign="bottom">0.6</td><td align="left" valign="bottom">Casein</td><td align="left" valign="bottom">20% protein66.9% carbs13.2% fat</td><td align="left" valign="bottom">CaseinCa Pi, dibasicNa Pi, dibasic</td></tr><tr><td align="left" valign="bottom">TD.170304(0.15% adenine)</td><td align="char" char="." valign="bottom">1.5</td><td align="char" char="." valign="bottom">0.9</td><td align="char" char="." valign="bottom">0.6</td><td align="left" valign="bottom">Casein</td><td align="left" valign="bottom">20% protein66.8% carbs13.2% fat</td><td align="left" valign="bottom">CaseinCa Pi, dibasicNa Pi, dibasic</td></tr><tr><td align="left" valign="bottom">TD.140290(0.2% adenine)</td><td align="char" char="." valign="bottom">2</td><td align="char" char="." valign="bottom">0.9</td><td align="char" char="." valign="bottom">0.6</td><td align="left" valign="bottom">Casein</td><td align="left" valign="bottom">20% protein66.8% carbs13.2% fat</td><td align="left" valign="bottom">CaseinCa Pi, dibasicNa Pi, dibasic</td></tr></tbody></table><table-wrap-foot><fn><p>Pi, phosphate; Ca, calcium; Na, sodium. These diets were manufactured by Envigo.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Composition of 0.7%, 2%, and 3% phosphate (Pi) diets.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Diet</th><th align="left" valign="bottom">Available Pi (%)</th><th align="left" valign="bottom">Total Ca (%)</th><th align="left" valign="bottom">Total iron (ppm)</th><th align="left" valign="bottom">Total K (%)</th><th align="left" valign="bottom">Total Na (%)</th><th align="left" valign="bottom">Protein source</th><th align="left" valign="bottom">Energy source</th><th align="left" valign="bottom">Pi source</th></tr></thead><tbody><tr><td align="left" valign="bottom">TD.180287(0.7% Pi diet)</td><td align="char" char="." valign="bottom">0.7</td><td align="char" char="." valign="bottom">1.9</td><td align="char" char="." valign="bottom">280</td><td align="char" char="." valign="bottom">2.4</td><td align="char" char="." valign="bottom">1.2</td><td align="left" valign="bottom">Crude</td><td align="left" valign="bottom">33.3% protein53.9% carbs12.8% fat</td><td align="left" valign="bottom">Crude protein</td></tr><tr><td align="left" valign="bottom">TD.08020(2% Pi diet)</td><td align="char" char="." valign="bottom">2.0</td><td align="char" char="." valign="bottom">1.9</td><td align="char" char="." valign="bottom">280</td><td align="char" char="." valign="bottom">1.8</td><td align="char" char="." valign="bottom">0.9</td><td align="left" valign="bottom">Crude</td><td align="left" valign="bottom">33.3% protein53.9% carbs12.8% fat</td><td align="left" valign="bottom">Crude proteinK Pi, monobasicNa Pi, monobasic</td></tr><tr><td align="left" valign="bottom">TD.180286(3% Pi diet)</td><td align="char" char="." valign="bottom">3.0</td><td align="char" char="." valign="bottom">1.9</td><td align="char" char="." valign="bottom">280</td><td align="char" char="." valign="bottom">2.4</td><td align="char" char="." valign="bottom">1.2</td><td align="left" valign="bottom">Crude</td><td align="left" valign="bottom">33.3% protein53.9% carbs12.8% fat</td><td align="left" valign="bottom">Crude proteinK Pi, monobasicNa Pi, monobasic</td></tr></tbody></table><table-wrap-foot><fn><p>Pi, phosphate; Ca, calcium; K, potassium; Na, sodium. These diets were manufactured by Envigo.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>Composition of 0.6% and 0.2% phosphate (Pi) diets.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Diet</th><th align="left" valign="bottom">Available Pi (%)</th><th align="left" valign="bottom">Total Ca (%)</th><th align="left" valign="bottom">Total iron (ppm)</th><th align="left" valign="bottom">Total K (%)</th><th align="left" valign="bottom">Total na (%)</th><th align="left" valign="bottom">Protein source</th><th align="left" valign="bottom">Energy source</th><th align="left" valign="bottom">Pi source</th></tr></thead><tbody><tr><td align="left" valign="bottom">TD.200407(0.6% Pi diet, normal)</td><td align="char" char="." valign="bottom">0.6</td><td align="char" char="." valign="bottom">0.6</td><td align="char" char="." valign="bottom">40</td><td align="char" char="." valign="bottom">0.6</td><td align="char" char="." valign="bottom">0.38</td><td align="left" valign="bottom">Egg white solids</td><td align="left" valign="bottom">17.7% protein65% carbs17.3% fat</td><td align="left" valign="bottom">Egg white solidsCa Pi, monobasic</td></tr><tr><td align="left" valign="bottom">TD.200406(0.2% Pi diet)</td><td align="char" char="." valign="bottom">0.2</td><td align="char" char="." valign="bottom">0.6</td><td align="char" char="." valign="bottom">40</td><td align="char" char="." valign="bottom">0.6</td><td align="char" char="." valign="bottom">0.38</td><td align="left" valign="bottom">Egg white solids</td><td align="left" valign="bottom">17.5% protein65.4% carbs17.1% fat</td><td align="left" valign="bottom">Egg white solidsCa Pi, monobasic</td></tr></tbody></table><table-wrap-foot><fn><p>Pi, phosphate; Ca, calcium; K, potassium; Na, sodium. These diets were manufactured by Envigo.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4-3"><title>Serum chemistry</title><p>Mouse blood was collected by cardiac puncture and transferred into microvette serum gel tubes (20.1344, Sarstedt). Samples were then centrifuged at 10,000 Ã <italic>g</italic> for 5 min at room temperature. Serum supernatants were harvested and stored at â80Â°C. Clinical chemistry analyses were performed by the Animal Histopathology &amp; Laboratory Medicine Core at the University of North Carolina, which is supported in part by an NCI Center Core Support Grant (5P30CA016086-41) to the UNC Lineberger Comprehensive Cancer Center. Serum intact FGF23 was assessed using ELISA (60-6800, Quidel).</p></sec><sec id="s4-4"><title>Grip-strength test</title><p>Muscle strength was assessed using a Chatillon DFE series digital force gauge (E-DFE-200, Chatillon) with a metal grid adaptor, provided by the Behavioral Assessment Core at UAB. Mice were allowed to grip the metal grid with fore- and hindlimbs and then gently pulled backwards by their tail, until mice could not grip the metal grid. Each mouse was given 10 trials, excluding the highest and lowest values. These eight trials were then averaged. These averaged values are used to represent the muscle grip strength of each individual mouse. Investigators were blinded to each experimental group.</p></sec><sec id="s4-5"><title>Mouse tissue collection</title><p>Unless otherwise indicated, tissues were excised, weighed, and either immediately flash frozen in liquid nitrogen or fixed for histologic examination. Organ and gastrocnemius weights were measured with an OHAUS scout portable balance (SJX323N/E).</p></sec><sec id="s4-6"><title>Histology</title><p>Spleen, kidney and gastrocnemius tissues were fixed in 10% formalin solution for 24 hr, transferred into 70% ethanol and subjected to paraffin embedding (IDEXX). Spleen, kidney, and gastrocnemius sections were cut and either stained with Perlsâ Prussian blue, H&amp;E, or Massonâs trichrome (IDEXX) and used for representative images. Images were captured on a Keyence BZ-X800 fluorescent microscope with a Ã20 and Ã40 objective lens.</p></sec><sec id="s4-7"><title>Tissue phosphate quantifications</title><p>To quantify liver phosphate concentrations in mouse tissue, liver samples were weighed, homogenized in protein precipitation solution (0.53 N HCl, 5.3% trichloroacetic acid [TCA]), boiled for 30 min at 95Â°C and cooled in room temperature water for 2 min. Samples were then centrifuged at 13,300 Ã <italic>g</italic> for 30 min at 4Â°C. Supernatants were collected and subjected to colorimetric phosphate quantifications (ab65622, Abcam) according to the manufacturesâ instructions.</p></sec><sec id="s4-8"><title>Tissue iron quantifications</title><p>To quantify nonheme iron concentrations in mouse tissues, spleen, and liver samples were weighed, homogenized in protein precipitation solution (0.53 N HCl, 5.3% TCA), boiled for 30 min at 95Â°C and cooled in room temperature water for 2 min. Samples were then centrifuged at 13,300 Ã <italic>g</italic> for 10 min at room temperature. Supernatants were harvested and subjected to colorimetric iron quantifications (157-30, Sekisui Diagnostics) according to the manufacturesâ instructions.</p></sec><sec id="s4-9"><title>Measurement of hematologic parameters and iron levels</title><p>Mouse blood was collected by cardiac puncture, transferred into microvette EDTA tubes (20.1341, Sarstedt), inverted to prevent clotting and stored at 4Â°C prior to shipment. Complete blood counts were measured by the Animal Histopathology &amp; Laboratory Medicine Core at the University of North Carolina. In addition, serum supernatants were analyzed for iron- and total iron-binding capacity (TIBC) concentrations. Transferrin saturation percentage (TSAT%) = (serum iron/TIBC) Ã 100.</p></sec><sec id="s4-10"><title>Isolation and cultivation of mouse primary hepatocytes</title><p>Hepatocytes were isolated from 10- to 14-week-old male wild-type C57BL/6J mice, which were anesthetized and placed on a 37Â°C heated surface to maintain adequate body temperature. Ventral laparotomy from the pubis to the cranial border of the liver was performed and the abdominal wall was incised to both sides, caudal of the diaphragm, exposing the inferior vena cava (IVC). Following suprahepatic diaphragm incision and surgical silk (5/0) ligation of the thoracic IVC, the infrarenal IVC was cannulated using a 24-Gauage shielded catheter (381412, BD) attached to a perfusion line. A peristaltic pump was utilized to perfuse the liver with 30 ml of liver perfusion medium (17701-038, Gibco) followed by 30 ml of liver digest medium (17703-034, Gibco), both prewarmed in a 37Â°C water bath. The portal vein was incised to route consecutive retrograde perfusion through the liver at a rate of 3 ml/min until each solution was empty. Next, the digested liver was excised, transferred into a 10-cm dish containing hepatocyte wash medium (17704-024, Gibco) and was minced within a cell culture hood. The mixture was then filtered through a 70-Î¼m nylon cell strainer (352350, Falcon) using a 20-ml plastic serological pipette into a 50-ml polypropylene conical tube (352098, Falcon) to remove debris. Cells were washed twice with chilled hepatocyte wash medium with centrifugation at 60 Ã <italic>g</italic> for 3 min at 4Â°C to allow a soft separation of parenchymal cells from nonparenchymal cells. To enrich the hepatocyte cell population, the cell pellet was resuspended and inverted four times in 20 ml of chilled 36% iso-osmotic percoll gradient solution (P1644, Sigma-Aldrich) (percoll gradient solution:Williamâs E medium solution [four parts:six parts]) and centrifuged at 200 Ã <italic>g</italic> for 7 min at 4Â°C. The enriched hepatocyte population was resuspended in 10 ml of chilled hepatocyte wash medium and subjected to two washes with centrifugation at 60 Ã <italic>g</italic> for 2 min at 4Â°C. The washed pellet was resuspended in 12 ml of warm Williamâs E medium (12551-032, Gibco) supplemented with primary hepatocyte thawing and plating supplements (CM3000, Gibco), counted in a hemocytometer after staining with trypan blue (25,900 Cl, Corning), seeded at a density of 2.5 Ã 10<sup>5</sup> cells/6-well or 1.0 Ã 10<sup>5</sup> cells/12-well on plates coated with 100 Î¼g/ml of collagen type 1 (354236, Corning) and allowed to adhere for 4 hr in a humidified 5% CO<sub>2</sub> incubator at 37Â°C. After this attachment period, medium was exchanged with fresh warm Williamâs E medium solution supplemented with primary hepatocyte maintenance supplements (CM4000, Gibco) and incubated overnight in a humidified 5% CO<sub>2</sub> incubator at 37Â°C. Next morning, media was exchanged with fresh warm Dulbecco's Modified Eagle's Medium (DMEM) (26140079, Gibco) supplemented with 1Ã penicillin/streptomycin (15140122, Gibco) and incubated for 6 hr in a humidified 5% CO<sub>2</sub> incubator at 37Â°C. This 6 hr serum-starvation period allows cells to synchronize to an identical cell cycle arrest phase, thus eliminating the potential impact between contrasting cell cycles and a cells overall response to exogenous treatment, as serum contains various growth factors and cytokines which promote the activation of signal transduction pathways related to cell proliferation and survival.</p></sec><sec id="s4-11"><title>Cell culture</title><p>Hepatocytes were isolated, cultivated, and serum starved as described in supplemental methods. For experiments investigating the activation of signal transduction mediators, cells were seeded on 6-well collagen-coated plates and treated with either TNFÎ± (100 ng/ml), IL6 (50 ng/ml), FGF23 (25 ng/ml), or appropriate amounts of sodium phosphate (1 M; pH 7.4) and sodium sulfate (1 M; pH 7.4) buffers to produce final desired concentrations and incubated for 30 min in a humidified 5% CO<sub>2</sub> incubator at 37Â°C. DMEM supplemented with 1Ã penicillin/streptomycin, which contains ~1 mM phosphate, served as a reference control (Ctrl). Sodium sulfate served as a negative control in response to increased anions.</p><p>For experiments analyzing expression levels of specific target genes, cells were seeded on 12-well collagen-coated plates and treated with either LPS (100 ng/ml), IL6 (50 ng/ml), or appropriate amounts of sodium phosphate (1 M; pH 7.4) and sodium sulfate (1 M; pH 7.4) buffers to produce final desired concentrations and incubated for 24 hr in a humidified 5% CO<sub>2</sub> incubator at 37Â°C. As described above, DMEM with 1Ã penicillin/streptomycin served as a reference control (Ctrl) and sodium sulfate served as a negative control.</p><p>For experiments investigating the role of high extracellular phosphate, cells were seeded on either 6- or 12-well collagen-coated plates and preincubated for 1 hr with or without the addition of PFA (1 mM) in a humidified 5% CO<sub>2</sub> incubator at 37Â°C. Cells were then either treated for 30 min to assess NFÎºB activation or treated for 24 hr to analyze expression levels of specific target genes, and incubated accordingly in a humidified 5% CO<sub>2</sub> incubator at 37Â°C. Specific treatments were conducted with factors described above. DMEM with 1Ã penicillin/streptomycin served as a reference control (Ctrl).</p><p>For experiments analyzing the participation of NFÎºB signaling, cells were seeded on 12-well collagen-coated plates and preincubated for 1 hr with or without the addition of BAY 11-7082 (20 Î¼M) in a humidified 5% CO<sub>2</sub> incubator at 37Â°C. Cells were then treated and incubated for 24 hr in a humidified 5% CO<sub>2</sub> incubator at 37Â°C to analyze expression levels of specific target genes. Specific treatments were conducted with factors described above. DMEM with 1Ã penicillin/streptomycin served as a reference control (Ctrl). Total protein lysates were prepared from 30-min treatments as described below. Total RNA was prepared from 24-hr treatments as described below. All 24-hr treatments were supplemented with 0.70% fetal bovine serum (FBS) (CM3000, Gibco).</p></sec><sec id="s4-12"><title>Cytokine neutralization</title><p>Hepatocytes were seeded on 12-well collagen-coated plates, cultivated and serum starved as described in supplemental methods. Primary mouse hepatocytes were treated for 24 hr to analyze expression levels of specific target genes with either LPS (100 ng/ml) or appropriate amounts of sodium phosphate buffer (1 M; pH 7.4) to produce a final desired phosphate concentration and incubated accordingly in a humidified 5% CO<sub>2</sub> incubator at 37Â°C. Treatments were performed with or without the addition of neutralizing antibodies against IL6 (6 Î¼g/ml) and/or IL1Î² (6 Î¼g/ml) as indicated. Total RNA was prepared from treatments as described below. All treatments were supplemented with 0.70% FBS (CM3000, Gibco).</p></sec><sec id="s4-13"><title>RNA isolation and quantification</title><p>Total RNA was extracted from liver and cultured hepatocytes using a RNeasy Plus Mini Kit (74136, Qiagen) and from gastrocnemius tissue using a RNeasy Plus Universal Mini Kit (73404, Qiagen) following the manufacturesâ instructions. Employing a two-step reaction method, 1 Î¼g of total RNA was reverse transcribed into cDNA using iScript Reverse Transcription Supermix (1708840, BioRad). Quantitative PCR was performed with 100 ng of cDNA, SsoAdvanced Universal SYBR Green Supermix (172-5272, BioRad) and sequence specific primers (as indicated in <xref ref-type="table" rid="table7">Table 7</xref>). Samples were run in duplicate on a CFX96 Touch Real-Time Detection Instrument (1855196, BioRad). Amplification was performed in forty cycles (95Â°C, 30 s; 98Â°C, 15 s; 60Â°C, 30 s; 65Â°C, 5 s). The generated amplicon was systematically double checked by its melting curve. Relative gene expression was normalized to expression levels of housekeeping genes <italic>18S rRNA</italic> (for in vitro studies) or <italic>Gapdh</italic> (for in vivo studies). Results were evaluated using the 2<sup>âââCt</sup> method and expressed as mean Â± standard error of the mean (SEM).</p><table-wrap id="table7" position="float"><label>Table 7.</label><caption><title>Oligonucleotides used as sequence specific primers in quantitative polymerase chain reaction (qPCR) analyses.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Gene</th><th align="left" valign="bottom">Species</th><th align="left" valign="bottom">Orientation</th><th align="left" valign="bottom">Primer sequence (5â²â3â²)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>Npt-1/Slc17a1</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">GGC ACC TCC CTT AGA ACG AGCAG AAC ACA CCC AAC AAT ACC AAA</td></tr><tr><td align="left" valign="bottom"><italic>Npt-4/Slc17a3</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">TGG TAC CCA TTG TTG CTG GCGGG ACA GCT TCA CAA ACG AGT</td></tr><tr><td align="left" valign="bottom"><italic>NaPi-2a/Slc34a1</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">TCA TTG TCA GCA TGG TCT CCT CCCT GCA AAA GCC CGC CTG</td></tr><tr><td align="left" valign="bottom"><italic>NaPi-2b/Slc34a2</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">CTC CTG CTG TCC CTT ACC TGTGT CAT TTG TTT TGC TGG CCT C</td></tr><tr><td align="left" valign="bottom"><italic>NaPi-2c/Slc34a3</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">GAT GCC TTT GAC CTG GTG GAGCC ATG CCA ACC TCT TTC AG</td></tr><tr><td align="left" valign="bottom"><italic>PiT-1/Slc20a1</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">TTC CTT GTT CGT GCG TTC ATCAAT TGG TAA AGC TCG TAA GCC ATT</td></tr><tr><td align="left" valign="bottom"><italic>PiT-2/Slc20a2</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">GAC CGT GGA AAC GCT AAT GGCTC AGG AAG GAC GCG ATC AA</td></tr><tr><td align="left" valign="bottom"><italic>Fgfr1</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">GCT TGA CGT CGT GGA ACG ATAGC CAC TGA ATG TGA GGC TG</td></tr><tr><td align="left" valign="bottom"><italic>Fgfr2</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">ATC CCC CTG CGG AGA CAGAG GAC AGA CGC GTT GTT ATC C</td></tr><tr><td align="left" valign="bottom"><italic>Fgfr3</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">GTG TGC GTG TAA CAG ATG CTCCGG GCG AGT CCA ATA AGG AG</td></tr><tr><td align="left" valign="bottom"><italic>Fgfr4</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">TGA AGA GTA CCT TGA CCT CCGTCA TGT CGT CTG CGA GTC AG</td></tr><tr><td align="left" valign="bottom"><italic>Alt1/Gpt1</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">GCC CTC GAG TAC TAT GCG TCTGT CTT GGT ATA CCT CAT CAG CC</td></tr><tr><td align="left" valign="bottom"><italic>Ast1/Got1</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">CTG AAT GAT CTG GAG AAT GCC CTGC AAA GCC CTG ATA GGC TG</td></tr><tr><td align="left" valign="bottom"><italic>Il6</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">CTC TGG GAA ATC GTG GAA ATCCA GTT TGG TAG CAT CCA TC</td></tr><tr><td align="left" valign="bottom"><italic>Il1b</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">TGC CAC CTT TTG ACA GTG ATGTGA TGT GCT GCT GCG AGA TT</td></tr><tr><td align="left" valign="bottom"><italic>Saa1</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">ACA CCA GCA GGA TGA AGC TAC TGAG CAT GGA AGT ATT TGT CTG AGT</td></tr><tr><td align="left" valign="bottom"><italic>Hamp</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">GAG CAG CAC CAC CTA TCT CCTTG GTA TCG CAA TGT CTG CC</td></tr><tr><td align="left" valign="bottom"><italic>Haptoglobin/Hp</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">AGA GAG GCA AGA GAG GTC CAGGC AGC TGT CAT CTT CAA AGT</td></tr><tr><td align="left" valign="bottom"><italic>Atrogin1/Fbxo32</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">TGA GCG ACC TCA GCA GTT ACGCG CTC CTT CGT ACT TCC TT</td></tr><tr><td align="left" valign="bottom"><italic>Murf1/Trim63</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">GAG GGC CAT TGA CTT TGG GATGG TGT TCT TCT TTA CCC TCT GT</td></tr><tr><td align="left" valign="bottom"><italic>Mstn</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">CTC CAG AAT AGA AGC CAT AGCA GAA GTT GTC TTA TAG C</td></tr><tr><td align="left" valign="bottom"><italic>Mt1</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">CGA CTT CAA CGT CCT GAG TACAGG AGC TGG TGC AAG TG</td></tr><tr><td align="left" valign="bottom"><italic>18S rRNA/Rn18s</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">TTG ACG GAA GGG CAC CAC CAGGCA CCA CCA CCC ACG GAA TCG</td></tr><tr><td align="left" valign="bottom"><italic>Gapdh</italic></td><td align="left" valign="bottom"><italic>Mus musculus</italic></td><td align="left" valign="bottom">ForwardReverse</td><td align="left" valign="bottom">CCA ATG TGT CCG TCG TGG ATC TGTT GAA GTC GCA GGA GAC AAC C</td></tr></tbody></table></table-wrap></sec><sec id="s4-14"><title>Protein isolation and immunoblotting</title><p>Total protein was extracted from cells which were placed on ice and scraped from 6- or 12-well plates, using a 300 or 150 Î¼l volume of RIPA lysis buffer (50 mM TrisâHCl, pH 7.5, 200 mM NaCl, 1% Triton X-100, 0.25% deoxycholic acid, 1 mM EDTA, 1 mM ethylene glycol-bis(Î²-aminoethyl ether)-N,N,Nâ²,Nâ²-tetraacetic acid tetrasodium (EGTA)), respectively, with addition of protease inhibitor (11836153001, Roche) and phosphatase inhibitors (P5726, P0044, Sigma-Aldrich). Cell lysates were then incubated on ice for 30 min and cleared by centrifugation at 13,000 Ã <italic>g</italic> for 30 min at 4Â°C. Supernatants were collected and protein was quantified using a Pierce BCA Protein Assay Kit (23225, Thermo Fisher Scientific).</p><p>Following protein quantification, supernatants were appropriately aliquoted and suspended in volumes of Laemmli sample buffer (1610747, BioRad) with Î²-mercaptoethanol (1610710, BioRad) as reducing agent, denatured at 100Â°C for 5 min and stored at â80Â°C. Protein samples [20 Î¼g total protein] were loaded onto 8% or 10% SDS polyacrylamide gels and separated by SDSâPAGE. Polyacrylamide gels were run in 1Ã Tris/Glycine/SDS buffer (1610732, BioRad) at 20 mA per gel and stopped when sample dyes reached the end of the gels. Proteins were electroblotted onto PVDF membranes (IPVH00010, Merck Millipore) via a semi-dry cassette (1703940, BioRad) in 1Ã Tris/Glycine Buffer (1610734, BioRad) with 20% methanol at 20 V for 1 hr. Membranes were then blocked in 5% nonfat dry milk with 0.1% Tween-20 diluted in 1Ã Tris buffered saline (TBS) pH 7.5 for 1 hr and probed with primary antibodies at 1:1000 against specific antigens overnight at 4Â°C. ERK1/2 (4695, Cell Signaling), STAT3 (4904, Cell Signaling), NFÎºB (8242, Cell Signaling), and Î²-actin (4970, Cell Signaling) primary antibodies were used in 1Ã TBS with 5% nonfat dry milk and 0.1% Tween-20. Phospho-ERK1/2 (9101, Cell Signaling), phospho-STAT3 (9145, Cell Signaling), and phospho-NFÎºB (3033, Cell Signaling) primary antibodies were used in 1Ã TBS with 5% BSA and 0.1% Tween-20.</p><p>Next day, membranes were subjected to three wash periods for 5 min in 1Ã TBS with 0.1% Tween and then probed with horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit secondary antibodies at 1:2,500 (W4021, W4011, Promega) in 1Ã TBS with 5% nonfat dry milk and 0.1% Tween at room temperature for 1 hr. Membranes were then subjected to three wash periods for 10 min in 1Ã TBS with 0.1% Tween at room temperature. Horseradish peroxidase activity was detected using enhanced chemiluminescence detection solution (RPN2106, GE Healthcare) and imaged on an SRX-101A X-ray film developer. All immunoblots were repeated with a minimum of three independent trials, with comparable results.</p></sec><sec id="s4-15"><title>Statistics</title><p>Data organization, scientific graphing, and statistical significance of differences between experimental groups were performed by using GraphPad Prism (version 9.0.0). All results are expressed as mean Â± SEM. Depending on number of experimental groups and factors analyzed, we performed a two-way analysis of variance (ANOVA) followed by a post hoc Tukey test (for studies affected by two factors) or in the form of a one-way ANOVA (for studies measuring variance in three groups or more). Correlation and slope analyses were examined by simple linear regression. Statistical significance was set at a p value of less than or equal to 0.05. Sample size was determined on the basis of sample availability, prior experimental studies performed in our laboratory and from prior literature. No formal randomization was used in any experiment. For in vivo experiments, animals were unbiasedly assigned into different experimental groups, regardless of genotype. Group allocation was not performed in a blinded manner. Whenever possible, investigators were blinded to experimental groups (e.g., analysis of all grip-strength measurements).</p></sec><sec id="s4-16"><title>Study approval</title><p>All animal protocols and experimental procedures for adenine diet in <italic>FGFR4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, graded phosphate diets in <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>â/â</sup></italic> mice, low phosphate diets in <italic>Col4a3<sup>+/+</sup></italic> and <italic>Col4a3<sup>â/â</sup></italic> mice and primary hepatocyte isolations from wild-type C57BL/6J mice, were approved by the Institutional Animal Care and Use Committees (IACUC) at the University of Alabama Birmingham School of Medicine. All animals were maintained in a ventilated rodent-housing system with temperature-controlled environments (22â23Â°C) with a 12-hr light/dark cycle and allowed ad libitum access to food and water. All protocols adhered to the Guide for Care and Use of Laboratory Animals to minimize pain and suffering. No animals were excluded from analysis.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>has received honoraria and grant support from Akebia and Amgen, grant support from GSK, honoraria from Ardelyx, Reata, and AstraZeneca, and serves on the Data Monitoring Committee for QED</p></fn><fn fn-type="COI-statement" id="conf3"><p>has ownership interest in Ferrumax Pharmaceuticals and has been a consultant for Incyte Corporation, and Alnylam Pharmaceuticals</p></fn><fn fn-type="COI-statement" id="conf4"><p>has served as a consultant for Bayer and Calico Labs, and he is the founder and currently the CSO of a startup biotech company (Alpha Young LLC)</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing â original draft</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con6"><p>Project administration</p></fn><fn fn-type="con" id="con7"><p>Conceptualization</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Methodology</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Investigation</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Writing â original draft</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal protocols and experimental procedures for adenine diet in FGFR4+/+ and FGFR4â/â mice, graded phosphate diets in FGFR4+/+ and FGFR4â/â mice, low phosphate diets in COL4A3+/+ and COL4A3â/â mice and primary hepatocyte isolations from wild-type C57BL/6J mice, were approved by the Institutional Animal Care and Use Committees (IACUC) at the University of Alabama Birmingham School of Medicine (#22089). All animals were maintained in a ventilated rodent-housing system with temperature-controlled environments (22â23Â°C) with a 12-hr light/dark cycle and allowed ad libitum access to food and water. All protocols adhered to the Guide for Care and Use of Laboratory Animals to minimize pain and suffering. No animals were excluded from analysis.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-74782-transrepform1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated and analyzed during this study are available through Dryad.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Data from: Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling full source data</data-title><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.6t1g1jx0f</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>BC designed and performed experiments, analyzed data, and wrote the manuscript. KH, IC, CY, DK, and DW assisted with experiments. GJ measured liver and spleen iron concentrations in Alport mice. OG, JBL, IBS, and MH assisted with data analysis and interpretation. CF supervised project, secured funding, assisted with data interpretation, and edited manuscript. All authors discussed results, read, and contributed edits to manuscript and approved final version.</p><p>This study was supported by NIH grants F31-DK-117550 (BC), T90-DE-022736 (KH), F31-DK-115074 (CY), K24-DK-116180 (OG), R01-DK-087727 (JLB), U01-DK-119950 (IBS), K08-DK-111980 (MH), R01-HL-128714, R01-HL-145528, and R01-DK-125459 (CF); and by grants from the Deutsche Forschungsgemeinschaft (DK) and the National Science Foundation (IC). Furthermore, CF was supported by the UAB-UCSD OâBrien Core Center for Acute Kidney Injury Research, the AMC21 program of the Department of Medicine at UAB and the Tolwani Innovation Award from the Division of Nephrology at UAB; JLB was supported by the Patricia and Scott Eston Massachusetts General Hospital Research Scholar Award.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acevedo</surname><given-names>LM</given-names></name><name><surname>LÃ³pez</surname><given-names>I</given-names></name><name><surname>Peralta-RamÃ­rez</surname><given-names>A</given-names></name><name><surname>Pineda</surname><given-names>C</given-names></name><name><surname>Chamizo</surname><given-names>VE</given-names></name><name><surname>RodrÃ­guez</surname><given-names>M</given-names></name><name><surname>Aguilera-Tejero</surname><given-names>E</given-names></name><name><surname>Rivero</surname><given-names>JLL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>High-phosphorus diet maximizes and low-dose calcitriol attenuates skeletal muscle changes in long-term uremic rats</article-title><source>Journal of Applied Physiology (Bethesda, Md)</source><volume>120</volume><fpage>1059</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00957.2015</pub-id><pub-id pub-id-type="pmid">26869708</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agoro</surname><given-names>R</given-names></name><name><surname>Montagna</surname><given-names>A</given-names></name><name><surname>Goetz</surname><given-names>R</given-names></name><name><surname>Aligbe</surname><given-names>O</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Coe</surname><given-names>LM</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Sitara</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia</article-title><source>FASEB Journal</source><volume>32</volume><fpage>3752</fpage><lpage>3764</lpage><pub-id pub-id-type="doi">10.1096/fj.201700667R</pub-id><pub-id pub-id-type="pmid">29481308</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amdur</surname><given-names>RL</given-names></name><name><surname>Feldman</surname><given-names>HI</given-names></name><name><surname>Gupta</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Kanetsky</surname><given-names>P</given-names></name><name><surname>Shlipak</surname><given-names>M</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Lash</surname><given-names>JP</given-names></name><name><surname>Townsend</surname><given-names>RR</given-names></name><name><surname>Ojo</surname><given-names>A</given-names></name><name><surname>Roy-Chaudhury</surname><given-names>A</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Joffe</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Balakrishnan</surname><given-names>VS</given-names></name><name><surname>Kimmel</surname><given-names>PL</given-names></name><name><surname>Kusek</surname><given-names>JW</given-names></name><name><surname>Raj</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Inflammation and Progression of CKD: The CRIC Study</article-title><source>Clin J Am Soc Nephro</source><volume>11</volume><fpage>1546</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.2215/cjn.13121215</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aschemeyer</surname><given-names>S</given-names></name><name><surname>Qiao</surname><given-names>B</given-names></name><name><surname>Stefanova</surname><given-names>D</given-names></name><name><surname>Valore</surname><given-names>EV</given-names></name><name><surname>Sek</surname><given-names>AC</given-names></name><name><surname>Ruwe</surname><given-names>TA</given-names></name><name><surname>Vieth</surname><given-names>KR</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>Casu</surname><given-names>C</given-names></name><name><surname>Rivella</surname><given-names>S</given-names></name><name><surname>Jormakka</surname><given-names>M</given-names></name><name><surname>Mackenzie</surname><given-names>B</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin</article-title><source>Blood</source><volume>131</volume><fpage>899</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-05-786590</pub-id><pub-id pub-id-type="pmid">29237594</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avin</surname><given-names>KG</given-names></name><name><surname>Vallejo</surname><given-names>JA</given-names></name><name><surname>Chen</surname><given-names>NX</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Touchberry</surname><given-names>CD</given-names></name><name><surname>Brotto</surname><given-names>M</given-names></name><name><surname>Dallas</surname><given-names>SL</given-names></name><name><surname>Moe</surname><given-names>SM</given-names></name><name><surname>Wacker</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility</article-title><source>American Journal of Physiology. Endocrinology and Metabolism</source><volume>315</volume><fpage>E594</fpage><lpage>E604</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00343.2017</pub-id><pub-id pub-id-type="pmid">29558205</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baquerizo</surname><given-names>A</given-names></name><name><surname>Anselmo</surname><given-names>D</given-names></name><name><surname>Shackleton</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>TW</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Weaver</surname><given-names>M</given-names></name><name><surname>Gornbein</surname><given-names>J</given-names></name><name><surname>Geevarghese</surname><given-names>S</given-names></name><name><surname>Nissen</surname><given-names>N</given-names></name><name><surname>Farmer</surname><given-names>D</given-names></name><name><surname>Demetriou</surname><given-names>A</given-names></name><name><surname>Busuttil</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Phosphorus ans an early predictive factor in patients with acute liver failure1</article-title><source>Transplantation</source><volume>75</volume><fpage>2007</fpage><lpage>2014</lpage><pub-id pub-id-type="doi">10.1097/01.TP.0000063219.21313.32</pub-id><pub-id pub-id-type="pmid">12829902</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BillesbÃ¸lle</surname><given-names>CB</given-names></name><name><surname>Azumaya</surname><given-names>CM</given-names></name><name><surname>Kretsch</surname><given-names>RC</given-names></name><name><surname>Powers</surname><given-names>AS</given-names></name><name><surname>Gonen</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Arvedson</surname><given-names>T</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Manglik</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms</article-title><source>Nature</source><volume>586</volume><fpage>807</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2668-z</pub-id><pub-id pub-id-type="pmid">32814342</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bon</surname><given-names>N</given-names></name><name><surname>Couasnay</surname><given-names>G</given-names></name><name><surname>Bourgine</surname><given-names>A</given-names></name><name><surname>Sourice</surname><given-names>S</given-names></name><name><surname>Beck-Cormier</surname><given-names>S</given-names></name><name><surname>Guicheux</surname><given-names>J</given-names></name><name><surname>Beck</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Phosphate (Pi)-regulated heterodimerization of the high-affinity sodium-dependent Pi transporters PiT1/Slc20a1 and PiT2/Slc20a2 underlies extracellular Pi sensing independently of Pi uptake</article-title><source>Journal of Biological Chemistry</source><volume>293</volume><fpage>2102</fpage><lpage>2114</lpage><pub-id pub-id-type="doi">10.1074/jbc.M117.807339</pub-id><pub-id pub-id-type="pmid">29233890</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrigan</surname><given-names>A</given-names></name><name><surname>Klinger</surname><given-names>A</given-names></name><name><surname>Choquette</surname><given-names>SS</given-names></name><name><surname>Luzuriaga-McPherson</surname><given-names>A</given-names></name><name><surname>Bell</surname><given-names>EK</given-names></name><name><surname>Darnell</surname><given-names>B</given-names></name><name><surname>GutiÃ©rrez</surname><given-names>OM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Contribution of Food Additives to Sodium and Phosphorus Content of Diets Rich in Processed Foods</article-title><source>Journal of Renal Nutrition</source><volume>24</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1053/j.jrn.2013.09.003</pub-id><pub-id pub-id-type="pmid">24355818</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>AR</given-names></name><name><surname>Lazo</surname><given-names>M</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>GutiÃ©rrez</surname><given-names>OM</given-names></name><name><surname>Grams</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III</article-title><source>The American Journal of Clinical Nutrition</source><volume>99</volume><fpage>320</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.3945/ajcn.113.073148</pub-id><pub-id pub-id-type="pmid">24225358</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavkin</surname><given-names>NW</given-names></name><name><surname>Chia</surname><given-names>JJ</given-names></name><name><surname>Crouthamel</surname><given-names>MH</given-names></name><name><surname>Giachelli</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells</article-title><source>Experimental Cell Research</source><volume>333</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2015.02.002</pub-id><pub-id pub-id-type="pmid">25684711</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chazot</surname><given-names>G</given-names></name><name><surname>Lemoine</surname><given-names>S</given-names></name><name><surname>Kocevar</surname><given-names>G</given-names></name><name><surname>Kalbacher</surname><given-names>E</given-names></name><name><surname>Sappey-Marinier</surname><given-names>D</given-names></name><name><surname>RouviÃ¨re</surname><given-names>O</given-names></name><name><surname>Juillard</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Intracellular Phosphate and ATP Depletion Measured by Magnetic Resonance Spectroscopy in Patients Receiving Maintenance Hemodialysis</article-title><source>Journal of the American Society of Nephrology</source><volume>32</volume><fpage>229</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1681/ASN.2020050716</pub-id><pub-id pub-id-type="pmid">33093193</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Kao</surname><given-names>TW</given-names></name><name><surname>Chou</surname><given-names>CW</given-names></name><name><surname>Wu</surname><given-names>CJ</given-names></name><name><surname>Yang</surname><given-names>HF</given-names></name><name><surname>Lai</surname><given-names>CH</given-names></name><name><surname>Wu</surname><given-names>LW</given-names></name><name><surname>Chen</surname><given-names>WL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Exploring the Link between Serum Phosphate Levels and Low Muscle Strength, Dynapenia, and Sarcopenia</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>3573</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-21784-1</pub-id><pub-id pub-id-type="pmid">29476104</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>LH</given-names></name><name><surname>Liu</surname><given-names>ST</given-names></name><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Salter</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>HS</given-names></name><name><surname>Hsu</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High phosphate induces skeletal muscle atrophy and suppresses myogenic differentiation by increasing oxidative stress and activating Nrf2 signaling</article-title><source>Aging</source><volume>12</volume><fpage>21446</fpage><lpage>21468</lpage><pub-id pub-id-type="doi">10.18632/aging.103896</pub-id><pub-id pub-id-type="pmid">33136552</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clerin</surname><given-names>V</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Filipski</surname><given-names>KJ</given-names></name><name><surname>Nguyen</surname><given-names>AH</given-names></name><name><surname>Garren</surname><given-names>J</given-names></name><name><surname>Kisucka</surname><given-names>J</given-names></name><name><surname>Reyes</surname><given-names>M</given-names></name><name><surname>JÃ¼ppner</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Selective pharmacological inhibition of the sodium-dependent phosphate co-transporter NPT2a promotes phosphate excretion</article-title><source>The Journal of Clinical Investigation</source><volume>130</volume><fpage>6510</fpage><lpage>6522</lpage><pub-id pub-id-type="doi">10.1172/JCI135665</pub-id><pub-id pub-id-type="pmid">32853180</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cosgrove</surname><given-names>D</given-names></name><name><surname>Meehan</surname><given-names>DT</given-names></name><name><surname>Grunkemeyer</surname><given-names>JA</given-names></name><name><surname>Kornak</surname><given-names>JM</given-names></name><name><surname>Sayers</surname><given-names>R</given-names></name><name><surname>Hunter</surname><given-names>WJ</given-names></name><name><surname>Samuelson</surname><given-names>GC</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome</article-title><source>Genes &amp; Development</source><volume>10</volume><fpage>2981</fpage><lpage>2992</lpage><pub-id pub-id-type="doi">10.1101/gad.10.23.2981</pub-id><pub-id pub-id-type="pmid">8956999</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czaya</surname><given-names>B</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>FGF23 and inflammationâa vicious coalition in CKD</article-title><source>Kidney International</source><volume>96</volume><fpage>813</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2019.05.018</pub-id><pub-id pub-id-type="pmid">31543148</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czaya</surname><given-names>B</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia</article-title><source>International Journal of Molecular Sciences</source><volume>20</volume><elocation-id>4195</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20174195</pub-id><pub-id pub-id-type="pmid">31461904</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erem</surname><given-names>S</given-names></name><name><surname>Razzaque</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dietary phosphate toxicity: an emerging global health concern</article-title><source>Histochemistry and Cell Biology</source><volume>150</volume><fpage>711</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1007/s00418-018-1711-8</pub-id><pub-id pub-id-type="pmid">30159784</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrow</surname><given-names>EG</given-names></name><name><surname>Imel</surname><given-names>EA</given-names></name><name><surname>White</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and Î±Klotho)</article-title><source>Best Practice &amp; Research Clinical Rheumatology</source><volume>25</volume><fpage>735</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1016/j.berh.2011.10.020</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>C</given-names></name><name><surname>Amaral</surname><given-names>AP</given-names></name><name><surname>Oskouei</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>M-C</given-names></name><name><surname>Sloan</surname><given-names>A</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>GutiÃ©rrez</surname><given-names>OM</given-names></name><name><surname>Aguillon-Prada</surname><given-names>R</given-names></name><name><surname>Lincoln</surname><given-names>J</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>Mundel</surname><given-names>P</given-names></name><name><surname>Morales</surname><given-names>A</given-names></name><name><surname>Scialla</surname><given-names>J</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Soliman</surname><given-names>EZ</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Rosas</surname><given-names>SE</given-names></name><name><surname>Nessel</surname><given-names>L</given-names></name><name><surname>Townsend</surname><given-names>RR</given-names></name><name><surname>Feldman</surname><given-names>HI</given-names></name><name><surname>St John Sutton</surname><given-names>M</given-names></name><name><surname>Ojo</surname><given-names>A</given-names></name><name><surname>Gadegbeku</surname><given-names>C</given-names></name><name><surname>Di Marco</surname><given-names>GS</given-names></name><name><surname>Reuter</surname><given-names>S</given-names></name><name><surname>Kentrup</surname><given-names>D</given-names></name><name><surname>Tiemann</surname><given-names>K</given-names></name><name><surname>Brand</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>JA</given-names></name><name><surname>Moe</surname><given-names>OW</given-names></name><name><surname>Kuro-O</surname><given-names>M</given-names></name><name><surname>Kusek</surname><given-names>JW</given-names></name><name><surname>Keane</surname><given-names>MG</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>FGF23 induces left ventricular hypertrophy</article-title><source>The Journal of Clinical Investigation</source><volume>121</volume><fpage>4393</fpage><lpage>4408</lpage><pub-id pub-id-type="doi">10.1172/JCI46122</pub-id><pub-id pub-id-type="pmid">21985788</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forand</surname><given-names>A</given-names></name><name><surname>Koumakis</surname><given-names>E</given-names></name><name><surname>Rousseau</surname><given-names>A</given-names></name><name><surname>Sassier</surname><given-names>Y</given-names></name><name><surname>Journe</surname><given-names>C</given-names></name><name><surname>Merlin</surname><given-names>JF</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Boitez</surname><given-names>V</given-names></name><name><surname>Codogno</surname><given-names>P</given-names></name><name><surname>Friedlander</surname><given-names>G</given-names></name><name><surname>Cohen</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Disruption of the Phosphate Transporter Pit1 in Hepatocytes Improves Glucose Metabolism and Insulin Signaling by Modulating the USP7/IRS1 Interaction</article-title><source>Cell Reports</source><volume>16</volume><fpage>2736</fpage><lpage>2748</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.012</pub-id><pub-id pub-id-type="pmid">27568561</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>C</given-names></name><name><surname>Courbon</surname><given-names>G</given-names></name><name><surname>Gerber</surname><given-names>C</given-names></name><name><surname>Neuburg</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Dussold</surname><given-names>C</given-names></name><name><surname>Capella</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Mehta</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>David</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease</article-title><source>Kidney International</source><volume>96</volume><fpage>1346</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2019.07.026</pub-id><pub-id pub-id-type="pmid">31668632</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukumoto</surname><given-names>S</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>FGF23 is a hormone-regulating phosphate metabolismâUnique biological characteristics of FGF23</article-title><source>Bone</source><volume>40</volume><fpage>1190</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2006.12.062</pub-id><pub-id pub-id-type="pmid">17276744</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Nemeth</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hepcidin and iron homeostasis</article-title><source>Biochimica et Biophysica Acta</source><volume>1823</volume><fpage>1434</fpage><lpage>1443</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.01.014</pub-id><pub-id pub-id-type="pmid">22306005</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabner</surname><given-names>A</given-names></name><name><surname>Amaral</surname><given-names>AP</given-names></name><name><surname>Schramm</surname><given-names>K</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Sloan</surname><given-names>A</given-names></name><name><surname>Yanucil</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shehadeh</surname><given-names>LA</given-names></name><name><surname>Hare</surname><given-names>JM</given-names></name><name><surname>David</surname><given-names>V</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Fornoni</surname><given-names>A</given-names></name><name><surname>Di Marco</surname><given-names>GS</given-names></name><name><surname>Kentrup</surname><given-names>D</given-names></name><name><surname>Reuter</surname><given-names>S</given-names></name><name><surname>Mayer</surname><given-names>AB</given-names></name><name><surname>PavenstÃ¤dt</surname><given-names>H</given-names></name><name><surname>Stypmann</surname><given-names>J</given-names></name><name><surname>Kuhn</surname><given-names>C</given-names></name><name><surname>Hille</surname><given-names>S</given-names></name><name><surname>Frey</surname><given-names>N</given-names></name><name><surname>Leifheit-Nestler</surname><given-names>M</given-names></name><name><surname>Richter</surname><given-names>B</given-names></name><name><surname>Haffner</surname><given-names>D</given-names></name><name><surname>Abraham</surname><given-names>R</given-names></name><name><surname>Bange</surname><given-names>J</given-names></name><name><surname>Sperl</surname><given-names>B</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Brand</surname><given-names>M</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy</article-title><source>Cell Metabolism</source><volume>22</volume><fpage>1020</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.09.002</pub-id><pub-id pub-id-type="pmid">26437603</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>GutiÃ©rrez</surname><given-names>OM</given-names></name><name><surname>Anderson</surname><given-names>C</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Scialla</surname><given-names>J</given-names></name><name><surname>Negrea</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>AH</given-names></name><name><surname>Bellovich</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>N</given-names></name><name><surname>Ojo</surname><given-names>A</given-names></name><name><surname>Lash</surname><given-names>J</given-names></name><name><surname>Feldman</surname><given-names>HI</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><collab>CRIC Study Group</collab></person-group><year iso-8601-date="2010">2010a</year><article-title>Low Socioeconomic Status Associates with Higher Serum Phosphate Irrespective of Race</article-title><source>Journal of the American Society of Nephrology</source><volume>21</volume><fpage>1953</fpage><lpage>1960</lpage><pub-id pub-id-type="doi">10.1681/ASN.2010020221</pub-id><pub-id pub-id-type="pmid">20847142</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>GutiÃ©rrez</surname><given-names>OM</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010b</year><article-title>Dietary Phosphorus Restriction in Advanced Chronic Kidney Disease: Merits, Challenges, and Emerging Strategies</article-title><source>Seminars in Dialysis</source><volume>23</volume><fpage>401</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1111/j.1525-139X.2010.00750.x</pub-id><pub-id pub-id-type="pmid">20557490</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Quarles</surname><given-names>LD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>138</volume><fpage>66</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2019.11.149</pub-id><pub-id pub-id-type="pmid">31758962</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haut</surname><given-names>LL</given-names></name><name><surname>Alfrey</surname><given-names>AC</given-names></name><name><surname>Guggenheim</surname><given-names>S</given-names></name><name><surname>Buddington</surname><given-names>B</given-names></name><name><surname>Schrier</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Renal toxicity of phosphate in rats</article-title><source>Kidney International</source><volume>17</volume><fpage>722</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1038/ki.1980.85</pub-id><pub-id pub-id-type="pmid">7412107</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>P</given-names></name><name><surname>Mann-Collura</surname><given-names>O</given-names></name><name><surname>Fling</surname><given-names>J</given-names></name><name><surname>Edara</surname><given-names>N</given-names></name><name><surname>Hetz</surname><given-names>R</given-names></name><name><surname>Razzaque</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>High phosphate actively induces cytotoxicity by rewiring proâsurvival and proâapoptotic signaling networks in HEK293 and HeLa cells</article-title><source>FASEB Journal</source><volume>35</volume><elocation-id>e20997</elocation-id><pub-id pub-id-type="doi">10.1096/fj.202000799RR</pub-id><pub-id pub-id-type="pmid">32892444</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshino</surname><given-names>J</given-names></name><name><surname>Muenz</surname><given-names>D</given-names></name><name><surname>Zee</surname><given-names>J</given-names></name><name><surname>Sukul</surname><given-names>N</given-names></name><name><surname>Speyer</surname><given-names>E</given-names></name><name><surname>Guedes</surname><given-names>M</given-names></name><name><surname>Lopes</surname><given-names>AA</given-names></name><name><surname>Asahi</surname><given-names>K</given-names></name><name><surname>van Haalen</surname><given-names>H</given-names></name><name><surname>James</surname><given-names>G</given-names></name><name><surname>Dhalwani</surname><given-names>N</given-names></name><name><surname>Pecoits-Filho</surname><given-names>R</given-names></name><name><surname>Bieber</surname><given-names>B</given-names></name><name><surname>Robinson</surname><given-names>BM</given-names></name><name><surname>Pisoni</surname><given-names>RL</given-names></name><collab>CKDopps Investigators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Associations of Hemoglobin Levels With Health-Related Quality of Life, Physical Activity, and Clinical Outcomes in Persons With Stage 3-5 Nondialysis CKD</article-title><source>Journal of Renal Nutrition</source><volume>30</volume><fpage>404</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1053/j.jrn.2019.11.003</pub-id><pub-id pub-id-type="pmid">31980326</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Gutierrez</surname><given-names>O</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Castaldo</surname><given-names>L</given-names></name><name><surname>Holmes</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in Early CKD</article-title><source>Journal of the American Society of Nephrology</source><volume>19</volume><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1681/ASN.2007060673</pub-id><pub-id pub-id-type="pmid">18216315</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>GutiÃ©rrez</surname><given-names>OM</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Tamez</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>K</given-names></name><name><surname>Thadhani</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Phosphorus Binders and Survival on Hemodialysis</article-title><source>Journal of the American Society of Nephrology</source><volume>20</volume><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1681/ASN.2008060609</pub-id><pub-id pub-id-type="pmid">19092121</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Wahl</surname><given-names>P</given-names></name><name><surname>Vargas</surname><given-names>GS</given-names></name><name><surname>GutiÃ©rrez</surname><given-names>OM</given-names></name><name><surname>Scialla</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Appleby</surname><given-names>D</given-names></name><name><surname>Nessel</surname><given-names>L</given-names></name><name><surname>Bellovich</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hamm</surname><given-names>L</given-names></name><name><surname>Gadegbeku</surname><given-names>C</given-names></name><name><surname>Horwitz</surname><given-names>E</given-names></name><name><surname>Townsend</surname><given-names>RR</given-names></name><name><surname>Anderson</surname><given-names>CAM</given-names></name><name><surname>Lash</surname><given-names>JP</given-names></name><name><surname>Hsu</surname><given-names>C-Y</given-names></name><name><surname>Leonard</surname><given-names>MB</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease</article-title><source>Kidney International</source><volume>79</volume><fpage>1370</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.47</pub-id><pub-id pub-id-type="pmid">21389978</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanamori</surname><given-names>Y</given-names></name><name><surname>Murakami</surname><given-names>M</given-names></name><name><surname>Sugiyama</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>O</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Funaba</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Interleukin-1Î² (IL-1Î²) transcriptionally activates hepcidin by inducing CCAAT enhancer-binding protein Î´ (C/EBPÎ´) expression in hepatocytes</article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>10275</fpage><lpage>10287</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.770974</pub-id><pub-id pub-id-type="pmid">28438835</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komaba</surname><given-names>H</given-names></name><name><surname>Fukagawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phosphateâa poison for humans?</article-title><source>Kidney International</source><volume>90</volume><fpage>753</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2016.03.039</pub-id><pub-id pub-id-type="pmid">27282935</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koumakis</surname><given-names>E</given-names></name><name><surname>Millet-Botti</surname><given-names>J</given-names></name><name><surname>Benna</surname><given-names>JE</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Boitez</surname><given-names>V</given-names></name><name><surname>Codogno</surname><given-names>P</given-names></name><name><surname>Friedlander</surname><given-names>G</given-names></name><name><surname>Forand</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Novel function of PiT1/SLC20A1 in LPS-related inflammation and wound healing</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>1808</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-37551-1</pub-id><pub-id pub-id-type="pmid">30755642</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovesdy</surname><given-names>CP</given-names></name><name><surname>Kopple</surname><given-names>JD</given-names></name><name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy</article-title><source>The American Journal of Clinical Nutrition</source><volume>97</volume><fpage>1163</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.3945/ajcn.112.036418</pub-id><pub-id pub-id-type="pmid">23636234</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lederer</surname><given-names>E</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Clinical Consequences of Mutations in Sodium Phosphate Cotransporters</article-title><source>Clinical Journal of the American Society of Nephrology</source><volume>7</volume><fpage>1179</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.2215/CJN.09090911</pub-id><pub-id pub-id-type="pmid">22516291</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leifheit-Nestler</surname><given-names>M</given-names></name><name><surname>Grabner</surname><given-names>A</given-names></name><name><surname>Hermann</surname><given-names>L</given-names></name><name><surname>Richter</surname><given-names>B</given-names></name><name><surname>Schmitz</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>DC</given-names></name><name><surname>Yanucil</surname><given-names>C</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name><name><surname>Haffner</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats</article-title><source>Nephrology, Dialysis, Transplantation</source><volume>32</volume><fpage>1493</fpage><lpage>1503</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfw454</pub-id><pub-id pub-id-type="pmid">28339837</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Moylan</surname><given-names>JS</given-names></name><name><surname>Chambers</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Interleukin-1 stimulates catabolism in C2C12 myotubes</article-title><source>Am J Physiol-Cell Ph</source><volume>297</volume><fpage>C706</fpage><lpage>C714</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00626.2008</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>R</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Hodakowski</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Leonard</surname><given-names>M</given-names></name><name><surname>Ricardo</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hamm</surname><given-names>L</given-names></name><name><surname>Sondheimer</surname><given-names>J</given-names></name><name><surname>Dobre</surname><given-names>M</given-names></name><name><surname>David</surname><given-names>V</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Go</surname><given-names>A</given-names></name><name><surname>Kusek</surname><given-names>JW</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Investigators</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study</article-title><source>Clinical Journal of the American Society of Nephrology</source><volume>12</volume><fpage>1795</fpage><lpage>1803</lpage><pub-id pub-id-type="doi">10.2215/CJN.03950417</pub-id><pub-id pub-id-type="pmid">28784656</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morishita</surname><given-names>K</given-names></name><name><surname>Shirai</surname><given-names>A</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Katakura</surname><given-names>Y</given-names></name><name><surname>Nabeshima</surname><given-names>Y</given-names></name><name><surname>Takeshige</surname><given-names>K</given-names></name><name><surname>Kamiya</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>The Progression of Aging in Klotho Mutant Mice Can Be Modified by Dietary Phosphorus and Zinc</article-title><source>The Journal of Nutrition</source><volume>131</volume><fpage>3182</fpage><lpage>3188</lpage><pub-id pub-id-type="doi">10.1093/jn/131.12.3182</pub-id><pub-id pub-id-type="pmid">11739863</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz Mendoza</surname><given-names>J</given-names></name><name><surname>Isakova</surname><given-names>T</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Bayes</surname><given-names>LY</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name><name><surname>Scialla</surname><given-names>JJ</given-names></name><name><surname>Lash</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Navaneethan</surname><given-names>S</given-names></name><name><surname>Negrea</surname><given-names>L</given-names></name><name><surname>Rosas</surname><given-names>SE</given-names></name><name><surname>Kretzler</surname><given-names>M</given-names></name><name><surname>Nessel</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>AH</given-names></name><name><surname>Raj</surname><given-names>DS</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><collab>CRIC Study Investigators</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease</article-title><source>Kidney International</source><volume>91</volume><fpage>711</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2016.10.021</pub-id><pub-id pub-id-type="pmid">28017325</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakao</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Nakahashi</surname><given-names>O</given-names></name><name><surname>Ikeda</surname><given-names>S</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>M</given-names></name><name><surname>Ishiguro</surname><given-names>M</given-names></name><name><surname>Iwano</surname><given-names>M</given-names></name><name><surname>Takeda</surname><given-names>E</given-names></name><name><surname>Taketani</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dietary phosphate supplementation delays the onset of iron deficiency anemia and affects iron status in rats</article-title><source>Nutrition Research (New York, N.Y.)</source><volume>35</volume><fpage>1016</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1016/j.nutres.2015.09.001</pub-id><pub-id pub-id-type="pmid">26475181</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro-GonzÃ¡lez</surname><given-names>JF</given-names></name><name><surname>Mora-FernÃ¡ndez</surname><given-names>C</given-names></name><name><surname>Muros</surname><given-names>M</given-names></name><name><surname>Herrera</surname><given-names>H</given-names></name><name><surname>GarcÃ­a</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mineral Metabolism and Inflammation in Chronic Kidney Disease Patients: A Cross-Sectional Study</article-title><source>Clinical Journal of the American Society of Nephrology</source><volume>4</volume><fpage>1646</fpage><lpage>1654</lpage><pub-id pub-id-type="doi">10.2215/CJN.02420409</pub-id><pub-id pub-id-type="pmid">19808245</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Rivera</surname><given-names>S</given-names></name><name><surname>Gabayan</surname><given-names>V</given-names></name><name><surname>Keller</surname><given-names>C</given-names></name><name><surname>Taudorf</surname><given-names>S</given-names></name><name><surname>Pedersen</surname><given-names>BK</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004a</year><article-title>IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin</article-title><source>The Journal of Clinical Investigation</source><volume>113</volume><fpage>1271</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1172/JCI20945</pub-id><pub-id pub-id-type="pmid">15124018</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemeth</surname><given-names>E</given-names></name><name><surname>Tuttle</surname><given-names>MS</given-names></name><name><surname>Powelson</surname><given-names>J</given-names></name><name><surname>Vaughn</surname><given-names>MB</given-names></name><name><surname>Donovan</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>DM</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004b</year><article-title>Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization</article-title><source>Science (New York, N.Y.)</source><volume>306</volume><fpage>2090</fpage><lpage>2093</lpage><pub-id pub-id-type="doi">10.1126/science.1104742</pub-id><pub-id pub-id-type="pmid">15514116</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noonan</surname><given-names>ML</given-names></name><name><surname>Clinkenbeard</surname><given-names>EL</given-names></name><name><surname>Ni</surname><given-names>P</given-names></name><name><surname>Swallow</surname><given-names>EA</given-names></name><name><surname>Tippen</surname><given-names>SP</given-names></name><name><surname>Agoro</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>MR</given-names></name><name><surname>White</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Erythropoietin and a hypoxiaâinducible factor prolyl hydroxylase inhibitor (HIFâPHDi) lowers FGF23 in a model of chronic kidney disease (CKD)</article-title><source>Physiological Reports</source><volume>8</volume><elocation-id>e14434</elocation-id><pub-id pub-id-type="doi">10.14814/phy2.14434</pub-id><pub-id pub-id-type="pmid">32476270</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>JW</given-names></name><name><surname>Schoenleber</surname><given-names>R</given-names></name><name><surname>Jesmok</surname><given-names>G</given-names></name><name><surname>Best</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>SA</given-names></name><name><surname>Collins</surname><given-names>T</given-names></name><name><surname>Gerritsen</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Novel Inhibitors of Cytokine-induced IÎºBÎ± Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo</article-title><source>The Journal of Biological Chemistry</source><volume>272</volume><fpage>21096</fpage><lpage>21103</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.34.21096</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>DSC</given-names></name><name><surname>Moseley</surname><given-names>P</given-names></name><name><surname>Dominic</surname><given-names>EA</given-names></name><name><surname>Onime</surname><given-names>A</given-names></name><name><surname>Tzamaloukas</surname><given-names>AH</given-names></name><name><surname>Boyd</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>VO</given-names></name><name><surname>Glew</surname><given-names>R</given-names></name><name><surname>Wolfe</surname><given-names>R</given-names></name><name><surname>Ferrando</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis</article-title><source>Kidney International</source><volume>73</volume><fpage>1054</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1038/ki.2008.21</pub-id><pub-id pub-id-type="pmid">18288103</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramnitz</surname><given-names>MS</given-names></name><name><surname>Gourh</surname><given-names>P</given-names></name><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name><name><surname>Wodajo</surname><given-names>F</given-names></name><name><surname>Ichikawa</surname><given-names>S</given-names></name><name><surname>Econs</surname><given-names>MJ</given-names></name><name><surname>White</surname><given-names>KE</given-names></name><name><surname>Molinolo</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>MY</given-names></name><name><surname>Heller</surname><given-names>T</given-names></name><name><surname>Del Rivero</surname><given-names>J</given-names></name><name><surname>Seo-Mayer</surname><given-names>P</given-names></name><name><surname>Arabshahi</surname><given-names>B</given-names></name><name><surname>Jackson</surname><given-names>MB</given-names></name><name><surname>Hatab</surname><given-names>S</given-names></name><name><surname>McCarthy</surname><given-names>E</given-names></name><name><surname>Guthrie</surname><given-names>LC</given-names></name><name><surname>Brillante</surname><given-names>BA</given-names></name><name><surname>Gafni</surname><given-names>RI</given-names></name><name><surname>Collins</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/HyperostosisâHyperphosphatemia Syndrome</article-title><source>Journal of Bone and Mineral Research</source><volume>31</volume><fpage>1845</fpage><lpage>1854</lpage><pub-id pub-id-type="doi">10.1002/jbmr.2870</pub-id><pub-id pub-id-type="pmid">27164190</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>RodrÃ­guez-Ortiz</surname><given-names>ME</given-names></name><name><surname>DÃ­az-Tocados</surname><given-names>JM</given-names></name><name><surname>MuÃ±oz-CastaÃ±eda</surname><given-names>JR</given-names></name><name><surname>Herencia</surname><given-names>C</given-names></name><name><surname>Pineda</surname><given-names>C</given-names></name><name><surname>MartÃ­nez-Moreno</surname><given-names>JM</given-names></name><name><surname>Montes de Oca</surname><given-names>A</given-names></name><name><surname>LÃ³pez-BaltanÃ¡s</surname><given-names>R</given-names></name><name><surname>AlcalÃ¡-DÃ­az</surname><given-names>J</given-names></name><name><surname>Ortiz</surname><given-names>A</given-names></name><name><surname>Aguilera-Tejero</surname><given-names>E</given-names></name><name><surname>Felsenfeld</surname><given-names>A</given-names></name><name><surname>RodrÃ­guez</surname><given-names>M</given-names></name><name><surname>AlmadÃ©n</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Inflammation both increases and causes resistance to FGF23 in normal and uremic rats</article-title><source>Clinical Science (London, England)</source><volume>134</volume><fpage>15</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1042/CS20190779</pub-id><pub-id pub-id-type="pmid">31860056</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaap</surname><given-names>LA</given-names></name><name><surname>Pluijm</surname><given-names>SMF</given-names></name><name><surname>Deeg</surname><given-names>DJH</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Inflammatory Markers and Loss of Muscle Mass (Sarcopenia) and Strength</article-title><source>The American Journal of Medicine</source><volume>119</volume><elocation-id>526</elocation-id><pub-id pub-id-type="doi">10.1016/j.amjmed.2005.10.049</pub-id><pub-id pub-id-type="pmid">16750969</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scialla</surname><given-names>JJ</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease</article-title><source>Nature Reviews. Nephrology</source><volume>10</volume><fpage>268</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2014.49</pub-id><pub-id pub-id-type="pmid">24686452</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiizaki</surname><given-names>K</given-names></name><name><surname>Tsubouchi</surname><given-names>A</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Seo</surname><given-names>K</given-names></name><name><surname>Kuchimaru</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Iwazu</surname><given-names>Y</given-names></name><name><surname>Miura</surname><given-names>M</given-names></name><name><surname>Battulga</surname><given-names>B</given-names></name><name><surname>Ohno</surname><given-names>N</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Kunishige</surname><given-names>R</given-names></name><name><surname>Masutani</surname><given-names>M</given-names></name><name><surname>Negishi</surname><given-names>K</given-names></name><name><surname>Kario</surname><given-names>K</given-names></name><name><surname>Kotani</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Nagata</surname><given-names>D</given-names></name><name><surname>Komuro</surname><given-names>I</given-names></name><name><surname>Itoh</surname><given-names>H</given-names></name><name><surname>Kurosu</surname><given-names>H</given-names></name><name><surname>Murata</surname><given-names>M</given-names></name><name><surname>Kuro-O</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Calcium phosphate microcrystals in the renal tubular fluid accelerate chronic kidney disease progression</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>145693</elocation-id><pub-id pub-id-type="doi">10.1172/JCI145693</pub-id><pub-id pub-id-type="pmid">34185705</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Grabner</surname><given-names>A</given-names></name><name><surname>Yanucil</surname><given-names>C</given-names></name><name><surname>Schramm</surname><given-names>K</given-names></name><name><surname>Czaya</surname><given-names>B</given-names></name><name><surname>Krick</surname><given-names>S</given-names></name><name><surname>Czaja</surname><given-names>MJ</given-names></name><name><surname>Bartz</surname><given-names>R</given-names></name><name><surname>Abraham</surname><given-names>R</given-names></name><name><surname>Di Marco</surname><given-names>GS</given-names></name><name><surname>Brand</surname><given-names>M</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease</article-title><source>Kidney International</source><volume>90</volume><fpage>985</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2016.05.019</pub-id><pub-id pub-id-type="pmid">27457912</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenvinkel</surname><given-names>P</given-names></name><name><surname>Carrero</surname><given-names>JJ</given-names></name><name><surname>von Walden</surname><given-names>F</given-names></name><name><surname>Ikizler</surname><given-names>TA</given-names></name><name><surname>Nader</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies</article-title><source>Nephrology, Dialysis, Transplantation</source><volume>31</volume><fpage>1070</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfv122</pub-id><pub-id pub-id-type="pmid">25910496</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugihara</surname><given-names>K</given-names></name><name><surname>Masuda</surname><given-names>M</given-names></name><name><surname>Nakao</surname><given-names>M</given-names></name><name><surname>Abuduli</surname><given-names>M</given-names></name><name><surname>Imi</surname><given-names>Y</given-names></name><name><surname>Oda</surname><given-names>N</given-names></name><name><surname>Okahisa</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>E</given-names></name><name><surname>Taketani</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dietary phosphate exacerbates intestinal inflammation in experimental colitis</article-title><source>Journal of Clinical Biochemistry and Nutrition</source><volume>61</volume><fpage>91</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.3164/jcbn.16-117</pub-id><pub-id pub-id-type="pmid">28955125</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takashi</surname><given-names>Y</given-names></name><name><surname>Kosako</surname><given-names>H</given-names></name><name><surname>Sawatsubashi</surname><given-names>S</given-names></name><name><surname>Kinoshita</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>N</given-names></name><name><surname>Tsoumpra</surname><given-names>MK</given-names></name><name><surname>Nangaku</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><name><surname>Matsuhisa</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Fukumoto</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation</article-title><source>PNAS</source><volume>116</volume><elocation-id>201815166</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.1815166116</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Yanucil</surname><given-names>C</given-names></name><name><surname>Musgrove</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Ide</surname><given-names>S</given-names></name><name><surname>Souma</surname><given-names>T</given-names></name><name><surname>Faul</surname><given-names>C</given-names></name><name><surname>Wolf</surname><given-names>M</given-names></name><name><surname>Grabner</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>FGFR4 does not contribute to progression of chronic kidney disease</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>14023</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-50669-0</pub-id><pub-id pub-id-type="pmid">31575945</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Murali</surname><given-names>SK</given-names></name><name><surname>Fenton</surname><given-names>RA</given-names></name><name><surname>Dominguez Rieg</surname><given-names>JA</given-names></name><name><surname>Rieg</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pharmacological Npt2a Inhibition Causes Phosphaturia and Reduces Plasma Phosphate in Mice with Normal and Reduced Kidney Function</article-title><source>Journal of the American Society of Nephrology</source><volume>30</volume><fpage>2128</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.1681/ASN.2018121250</pub-id><pub-id pub-id-type="pmid">31409727</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toussaint</surname><given-names>ND</given-names></name><name><surname>Pedagogos</surname><given-names>E</given-names></name><name><surname>Lioufas</surname><given-names>NM</given-names></name><name><surname>Elder</surname><given-names>GJ</given-names></name><name><surname>Pascoe</surname><given-names>EM</given-names></name><name><surname>Badve</surname><given-names>SV</given-names></name><name><surname>Valks</surname><given-names>A</given-names></name><name><surname>Block</surname><given-names>GA</given-names></name><name><surname>Boudville</surname><given-names>N</given-names></name><name><surname>Cameron</surname><given-names>JD</given-names></name><name><surname>Campbell</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>SSM</given-names></name><name><surname>Faull</surname><given-names>RJ</given-names></name><name><surname>Holt</surname><given-names>SG</given-names></name><name><surname>Jackson</surname><given-names>D</given-names></name><name><surname>Jardine</surname><given-names>MJ</given-names></name><name><surname>Johnson</surname><given-names>DW</given-names></name><name><surname>Kerr</surname><given-names>PG</given-names></name><name><surname>Lau</surname><given-names>KK</given-names></name><name><surname>Hooi</surname><given-names>LS</given-names></name><name><surname>Narayan</surname><given-names>O</given-names></name><name><surname>Perkovic</surname><given-names>V</given-names></name><name><surname>Polkinghorne</surname><given-names>KR</given-names></name><name><surname>Pollock</surname><given-names>CA</given-names></name><name><surname>Reidlinger</surname><given-names>D</given-names></name><name><surname>Robison</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>ER</given-names></name><name><surname>Walker</surname><given-names>RJ</given-names></name><name><surname>Wang</surname><given-names>AYM</given-names></name><name><surname>Hawley</surname><given-names>CM</given-names></name><name><surname>Investigators</surname><given-names>ICT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD</article-title><source>Journal of the American Society of Nephrology</source><volume>31</volume><fpage>2653</fpage><lpage>2666</lpage><pub-id pub-id-type="doi">10.1681/ASN.2020040411</pub-id><pub-id pub-id-type="pmid">32917784</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>L</given-names></name><name><surname>Batech</surname><given-names>M</given-names></name><name><surname>Rhee</surname><given-names>CM</given-names></name><name><surname>Streja</surname><given-names>E</given-names></name><name><surname>Kalantar-Zadeh</surname><given-names>K</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><name><surname>Sim</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Serum phosphorus and association with anemia among a large diverse population with and without chronic kidney disease</article-title><source>Nephrology, Dialysis, Transplantation</source><volume>31</volume><fpage>636</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfv297</pub-id><pub-id pub-id-type="pmid">26254460</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>ME</given-names></name><name><surname>Lansing</surname><given-names>AP</given-names></name><name><surname>Jeronimo</surname><given-names>PS</given-names></name><name><surname>Lee</surname><given-names>LH</given-names></name><name><surname>Svajger</surname><given-names>BA</given-names></name><name><surname>Zelt</surname><given-names>JG</given-names></name><name><surname>Forster</surname><given-names>CM</given-names></name><name><surname>Petkovich</surname><given-names>MP</given-names></name><name><surname>Holden</surname><given-names>RM</given-names></name><name><surname>Adams</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Vascular Calcification Has a Role in Acute Non-Renal Phosphate Clearance</article-title><source>BioRxiv</source><source>Pathology</source><pub-id pub-id-type="doi">10.1101/2020.07.29.225532</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ugrica</surname><given-names>M</given-names></name><name><surname>Bettoni</surname><given-names>C</given-names></name><name><surname>Bourgeois</surname><given-names>S</given-names></name><name><surname>Daryadel</surname><given-names>A</given-names></name><name><surname>Pastor-Arroyo</surname><given-names>EM</given-names></name><name><surname>Gehring</surname><given-names>N</given-names></name><name><surname>Hernando</surname><given-names>N</given-names></name><name><surname>Wagner</surname><given-names>CA</given-names></name><name><surname>Rubio-Aliaga</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A chronic high phosphate intake in mice is detrimental for bone health without major renal alterations</article-title><source>Nephrology, Dialysis, Transplantation</source><volume>36</volume><fpage>1183</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfab015</pub-id><pub-id pub-id-type="pmid">33515264</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verga Falzacappa</surname><given-names>MV</given-names></name><name><surname>Vujic Spasic</surname><given-names>M</given-names></name><name><surname>Kessler</surname><given-names>R</given-names></name><name><surname>Stolte</surname><given-names>J</given-names></name><name><surname>Hentze</surname><given-names>MW</given-names></name><name><surname>Muckenthaler</surname><given-names>MU</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation</article-title><source>Blood</source><volume>109</volume><fpage>353</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-07-033969</pub-id><pub-id pub-id-type="pmid">16946298</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verzola</surname><given-names>D</given-names></name><name><surname>Bonanni</surname><given-names>A</given-names></name><name><surname>Sofia</surname><given-names>A</given-names></name><name><surname>Montecucco</surname><given-names>F</given-names></name><name><surname>DâAmato</surname><given-names>E</given-names></name><name><surname>Cademartori</surname><given-names>V</given-names></name><name><surname>Parodi</surname><given-names>EL</given-names></name><name><surname>Viazzi</surname><given-names>F</given-names></name><name><surname>Venturelli</surname><given-names>C</given-names></name><name><surname>Brunori</surname><given-names>G</given-names></name><name><surname>Garibotto</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tollâlike receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease</article-title><source>Journal of Cachexia, Sarcopenia and Muscle</source><volume>8</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1002/jcsm.12129</pub-id><pub-id pub-id-type="pmid">27897392</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verzola</surname><given-names>D</given-names></name><name><surname>Barisione</surname><given-names>C</given-names></name><name><surname>Picciotto</surname><given-names>D</given-names></name><name><surname>Garibotto</surname><given-names>G</given-names></name><name><surname>Koppe</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Emerging role of myostatin and its inhibition in the setting of chronic kidney disease</article-title><source>Kidney International</source><volume>95</volume><fpage>506</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2018.10.010</pub-id><pub-id pub-id-type="pmid">30598193</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa-Bellosta</surname><given-names>R</given-names></name><name><surname>Bogaert</surname><given-names>YE</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>Sorribas</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Characterization of Phosphate Transport in Rat Vascular Smooth Muscle Cells</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>27</volume><fpage>1030</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.106.132266</pub-id><pub-id pub-id-type="pmid">17322102</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa-Bellosta</surname><given-names>R</given-names></name><name><surname>Sorribas</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Phosphonoformic Acid Prevents Vascular Smooth Muscle Cell Calcification by Inhibiting Calcium-Phosphate Deposition</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>29</volume><fpage>761</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.108.183384</pub-id><pub-id pub-id-type="pmid">19213941</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voelkl</surname><given-names>J</given-names></name><name><surname>Tuffaha</surname><given-names>R</given-names></name><name><surname>Luong</surname><given-names>TTD</given-names></name><name><surname>Zickler</surname><given-names>D</given-names></name><name><surname>Masyout</surname><given-names>J</given-names></name><name><surname>Feger</surname><given-names>M</given-names></name><name><surname>Verheyen</surname><given-names>N</given-names></name><name><surname>Blaschke</surname><given-names>F</given-names></name><name><surname>Kuro-O</surname><given-names>M</given-names></name><name><surname>Tomaschitz</surname><given-names>A</given-names></name><name><surname>Pilz</surname><given-names>S</given-names></name><name><surname>Pasch</surname><given-names>A</given-names></name><name><surname>Eckardt</surname><given-names>K-U</given-names></name><name><surname>Scherberich</surname><given-names>JE</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name><name><surname>Alesutan</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Zinc Inhibits Phosphate-Induced Vascular Calcification through TNFAIP3-Mediated Suppression of NF-ÎºB</article-title><source>Journal of the American Society of Nephrology</source><volume>29</volume><fpage>1636</fpage><lpage>1648</lpage><pub-id pub-id-type="doi">10.1681/ASN.2017050492</pub-id><pub-id pub-id-type="pmid">29654213</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XH</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mechanisms of muscle wasting in chronic kidney disease</article-title><source>Nature Reviews. Nephrology</source><volume>10</volume><fpage>504</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1038/nrneph.2014.112</pub-id><pub-id pub-id-type="pmid">24981816</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinstein</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Ohyama</surname><given-names>K</given-names></name><name><surname>Deng</surname><given-names>CX</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung</article-title><source>Development (Cambridge, England)</source><volume>125</volume><fpage>3615</fpage><lpage>3623</lpage><pub-id pub-id-type="doi">10.1242/dev.125.18.3615</pub-id><pub-id pub-id-type="pmid">9716527</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>KE</given-names></name><name><surname>Carn</surname><given-names>G</given-names></name><name><surname>Lorenz-Depiereux</surname><given-names>B</given-names></name><name><surname>Benet-Pages</surname><given-names>A</given-names></name><name><surname>Strom</surname><given-names>TM</given-names></name><name><surname>Econs</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23</article-title><source>Kidney International</source><volume>60</volume><fpage>2079</fpage><lpage>2086</lpage><pub-id pub-id-type="doi">10.1046/j.1523-1755.2001.00064.x</pub-id><pub-id pub-id-type="pmid">11737582</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojcicki</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hyperphosphatemia is associated with anemia in adults without chronic kidney disease: results from the National Health and Nutrition Examination Survey (NHANES): 2005â2010</article-title><source>BMC Nephrology</source><volume>14</volume><elocation-id>178</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2369-14-178</pub-id><pub-id pub-id-type="pmid">23965134</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Update on fibroblast growth factor 23 in chronic kidney disease</article-title><source>Kidney International</source><volume>82</volume><fpage>737</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.1038/ki.2012.176</pub-id><pub-id pub-id-type="pmid">22622492</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>King</surname><given-names>G</given-names></name><name><surname>Mancarella</surname><given-names>S</given-names></name><name><surname>Munkhsaikhan</surname><given-names>U</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Quarles</surname><given-names>LD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>FGF23 expression is stimulated in transgenic Î±-Klotho longevity mouse model</article-title><source>JCI Insight</source><volume>4</volume><elocation-id>132820</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.132820</pub-id><pub-id pub-id-type="pmid">31801907</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>S</given-names></name><name><surname>Tokumoto</surname><given-names>M</given-names></name><name><surname>Tatsumoto</surname><given-names>N</given-names></name><name><surname>Taniguchi</surname><given-names>M</given-names></name><name><surname>Noguchi</surname><given-names>H</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Masutani</surname><given-names>K</given-names></name><name><surname>Ooboshi</surname><given-names>H</given-names></name><name><surname>Tsuruya</surname><given-names>K</given-names></name><name><surname>Kitazono</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia</article-title><source>American Journal of Physiology. Renal Physiology</source><volume>306</volume><fpage>1418</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00633.2013</pub-id><pub-id pub-id-type="pmid">24808541</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelt</surname><given-names>JG</given-names></name><name><surname>Svajger</surname><given-names>BA</given-names></name><name><surname>Quinn</surname><given-names>K</given-names></name><name><surname>Turner</surname><given-names>ME</given-names></name><name><surname>Laverty</surname><given-names>KJ</given-names></name><name><surname>Shum</surname><given-names>B</given-names></name><name><surname>Holden</surname><given-names>RM</given-names></name><name><surname>Adams</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Acute Tissue Mineral Deposition in Response to a Phosphate Pulse in Experimental CKD</article-title><source>Journal of Bone and Mineral Research</source><volume>34</volume><fpage>270</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1002/jbmr.3572</pub-id><pub-id pub-id-type="pmid">30216554</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Rajan</surname><given-names>V</given-names></name><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>HQ</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Min</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease</article-title><source>FASEB Journal</source><volume>25</volume><fpage>1653</fpage><lpage>1663</lpage><pub-id pub-id-type="doi">10.1096/fj.10-176917</pub-id><pub-id pub-id-type="pmid">21282204</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Tweardy</surname><given-names>DJ</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Garibotto</surname><given-names>G</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Stat3 Activation Links a C/EBPÎ´ to Myostatin Pathway to Stimulate Loss of Muscle Mass</article-title><source>Cell Metabolism</source><volume>18</volume><fpage>368</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.07.012</pub-id><pub-id pub-id-type="pmid">24011072</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>MM</given-names></name><name><surname>Xu</surname><given-names>MJ</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo</article-title><source>Kidney International</source><volume>79</volume><fpage>1071</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1038/ki.2011.18</pub-id><pub-id pub-id-type="pmid">21368742</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>MJ</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Hepatocytes: a key cell type for innate immunity</article-title><source>Cellular &amp; Molecular Immunology</source><volume>13</volume><fpage>301</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1038/cmi.2015.97</pub-id><pub-id pub-id-type="pmid">26685902</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74782.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shoback</surname><given-names>Dolores</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>Many of us have followed the work of your group and others on FGF23 excess and hyperphosphatemia and the morbidity of chronic kidney disease in both animal models and in the human disease state. Inflammation, anemia and muscle wasting are clearcut serious consequences to deal with CKD. Animal models that will allow us to further elucidate the signaling and effector pathways activated by hyperphosphatemia are welcome advances in the field.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74782.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shoback</surname><given-names>Dolores</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>University of California, San Francisco</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Fukumoto</surname><given-names>Seiji</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/044vy1d05</institution-id><institution>Tokushima University</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Razzaque</surname><given-names>Mohammed S</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04679fh62</institution-id><institution>Lake Erie College of Osteopathic Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Seiji Fukumoto (Reviewer #1); Mohammed S Razzaque (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Please see the reviews listed below.</p><p>We feel the essential things to revise are the following.</p><p>From Reviewer #1:</p><p>1. It is not clearly shown why model mice of Alport syndrome rather than adenine-induced CKD model were used for examining effects of low phosphate diet.</p><p>2. It is difficult to see where iron is deposited by the figures. Higher magnification figures are necessary.</p><p>3. It is not clear where the supplemental Materials and methods are (l. 566, 576, 585â¦.).</p><p>4. Histology of muscle sections seems to be quite different between groups (For example Figure 3E). How were these sections selected?</p><p>From Reviewer #3:</p><p>1. Can you speak to this point please?</p><p>This manuscript is technically sound and addresses an important issue of the direct effect of excessive phosphate in inducing inflammation. The authors also tried to connect the high phosphate and skeletal muscle wasting or anemia to give relevance to chronic kidney disease. The authors also ruled out the involvement of FGF23-FGFR4 in iron deficiency by providing convincing evidence of mouse genetics.</p><p>2. Can you address these requests please?</p><p>The results are of interest and the readership will benefit from the following modifications/ clarifications:</p><p>A. The reviewer realizes that the heart is not the focus of this study, considering the authors have shown the involvement of FGF23-FGFR4 signaling in cardiac hypertrophy; commenting on the FGF23-FGFR4-independent effects of high phosphate on cardiac structure or function would be useful to know. In other words, do the high phosphate has a differential impact on cardiac vs. skeletal muscle?</p><p>B. For a high phosphate-induced downstream signaling cascade (Figure 6), the authors should consider explaining their results in the context of the global cytotoxic signaling cascade generated following excessive phosphate exposure (PMID: 32892444).</p><p>C. It would be nice to know how phosphate activates Pit1 and Pit2?</p><p>D. The part of the Discussion section is the repetition of the result section, and the authors should consider minimizing the overlap.</p><p>Can you please make the revisions and adjustments requested? We are enthusiastic about this paper. Thank you.</p><p><italic>Reviewer #1:</italic></p><p>The authors investigated the effects of phosphate on the development of several complications of chronic kidney disease (CKD) such as inflammation, anemia, and skeletal muscle wasting using several animal models. They showed that phosphate induced these complications in adenine-induced CKD model and mice fed with high phosphate diet in FGFR4 independent manner. They also showed that a low phosphate diet improved these in model mice of Alport syndrome. Then, they investigated the actions of phosphate using primary hepatocytes and indicated that phosphate induced the expression of several inflammatory cytokines. These data reveal the new function of phosphate and are potentially important for the understanding and the management of the complication of CKD.</p><p>Strengths</p><p>The authors used several established in vivo models of CKD. Data obtained in these in vivo experiments are clear and reproducible in multiple models.</p><p>They showed novel actions of phosphate in the development of complications of CKD.</p><p>Weaknesses</p><p>Several in vitro experiments did not completely reveal the underlying mechanism of the actions of phosphate. It is not clear how phosphate phosphorylates P65. The effects of phosphate on enhanced phosphorylation of P65 were not dose-dependent (Figure 6A). It is not shown whether phosphate affected the expression of TNFÎ± while TNFÎ± is a potent activator of NFÎºB (Figure 6A). It is not shown either whether IL1Î² had the same effects on the expressions of cytokines and hepcidine. A scheme summarizing in vitro results and proposing the mechanism of phosphate might be helpful.</p><p>Mechanistic investigations on muscle wasting are lacking.</p><p>1. It is not clearly shown why model mice of Alport syndrome rather than adenine-induced CKD model were used for examining effects of low phosphate diet.</p><p>2. It is difficult to see where iron is deposited by the figures. Higher magnification figures are necessary.</p><p>3. It is not clear where the supplemental Materials and methods are (l. 566, 576, 585â¦.).</p><p>4. Histology of muscle sections seems to be quite different between groups (For example Figure 3E). How were these sections selected?</p><p><italic>Reviewer #3:</italic></p><p>This manuscript focuses on the impact of high phosphate on skeletal muscle injury and beyond. Although there are gaps, this manuscript would likely to form the basis for further in-depth studies.</p><p>This manuscript is technically sound and addresses an important issue of the direct effect of excessive phosphate in inducing inflammation. The authors also tried to connect the high phosphate and skeletal muscle wasting or anemia to give relevance to chronic kidney disease. The authors also ruled out the involvement of FGF23-FGFR4 in iron deficiency by providing convincing evidence of mouse genetics.</p><p>The results are of interest and the readership will benefit from the following modifications/ clarifications:</p><p>The reviewer realizes that the heart is not the focus of this study, considering the authors have shown the involvement of FGF23-FGFR4 signaling in cardiac hypertrophy; commenting on the FGF23-FGFR4-independent effects of high phosphate on cardiac structure or function would be useful to know. In other words, do the high phosphate has a differential impact on cardiac vs. skeletal muscle?</p><p>For a high phosphate-induced downstream signaling cascade (Figure 6), the authors should consider explaining their results in the context of the global cytotoxic signaling cascade generated following excessive phosphate exposure (PMID: 32892444).</p><p>It would be nice to know how phosphate activates Pit1 and Pit2?</p><p>The part of the Discussion section is the repetition of the result section, and the authors should consider minimizing the overlap.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.74782.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Can you please make the revisions and adjustments requested? We are enthusiastic about this paper. Thank you.</p></disp-quote><p>We thank the Editors for being enthusiastic about our work, for giving us the opportunity to respond to the Reviewersâ insightful and constructive comments, and for inviting us to submit a revised manuscript. Our specific responses to the Reviewers' comments are presented below in point-by-point fashion. We now submit a revised manuscript with alterations, highlighted in yellow, and we hope that the revised manuscript is suitable for publication in <italic>eLife</italic>.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>The authors investigated the effects of phosphate on the development of several complications of chronic kidney disease (CKD) such as inflammation, anemia, and skeletal muscle wasting using several animal models. They showed that phosphate induced these complications in adenine-induced CKD model and mice fed with high phosphate diet in FGFR4 independent manner. They also showed that a low phosphate diet improved these in model mice of Alport syndrome. Then, they investigated the actions of phosphate using primary hepatocytes and indicated that phosphate induced the expression of several inflammatory cytokines. These data reveal the new function of phosphate and are potentially important for the understanding and the management of the complication of CKD.</p></disp-quote><p>We thank the Reviewer for the positive feedback and for recognizing the novelty of our work.</p><disp-quote content-type="editor-comment"><p>Strengths</p><p>The authors used several established in vivo models of CKD. Data obtained in these in vivo experiments are clear and reproducible in multiple models.</p><p>They showed novel actions of phosphate in the development of complications of CKD.</p><p>Weaknesses</p><p>Several in vitro experiments did not completely reveal the underlying mechanism of the actions of phosphate. It is not clear how phosphate phosphorylates P65. The effects of phosphate on enhanced phosphorylation of P65 were not dose-dependent (Figure 6A). It is not shown whether phosphate affected the expression of TNFÎ± while TNFÎ± is a potent activator of NFÎºB (Figure 6A). It is not shown either whether IL1Î² had the same effects on the expressions of cytokines and hepcidine. A scheme summarizing in vitro results and proposing the mechanism of phosphate might be helpful.</p></disp-quote><p>We thank the Reviewer for this suggestion. We now present a schematic of the model and pathomechanism, including the signaling events in hepatocytes, in new Figure 8.</p><disp-quote content-type="editor-comment"><p>Mechanistic investigations on muscle wasting are lacking.</p></disp-quote><p>We agree with the Reviewer. We are currently investigating the exact impact on skeletal muscle, including the underlying pathomechanism in myotubes. However, we believe that this aspect is beyond the scope of the manuscript.</p><disp-quote content-type="editor-comment"><p>1. It is not clearly shown why model mice of Alport syndrome rather than adenine-induced CKD model were used for examining effects of low phosphate diet.</p></disp-quote><p>Adenine diet-induced nephropathy as a mouse model of CKD can be heterogeneous, ranging from a mild/no phenotype to a massive/lethal phenotype. Additionally, examining whether dietary phosphate restriction could represent a potential clinical treatment in this specific mouse model would be challenging, due to its phenotypic heterogeneity and subsequent diet already supplied. Designing a phosphate-restricted diet containing adenine, including proper control diets, would be challenging. After careful consideration, to investigate the potential of a low phosphate diet as clinical treatment, Alport mice were chosen. As an established genetic model of CKD, Alport mice provide a greater degree of phenotypic homogeneity, along with the development of endogenous hyperphosphatemia with severe inflammation, anemia and skeletal muscle wasting, overall making them an ideal candidate for dietary intervention.</p><disp-quote content-type="editor-comment"><p>2. It is difficult to see where iron is deposited by the figures. Higher magnification figures are necessary.</p></disp-quote><p>We have now included larger magnifications of spleen tissue sections stained with Perlâs Prussian blue from <italic>Fgfr4<sup>+/+</sup></italic> and <italic>Fgfr4<sup>-/-</sup></italic> mice fed either adenine diet or a graded dietary phosphate (Pi) load, as well as from wild-type (<italic>Col4a3<sup>+/+</sup></italic>) and Alport (<italic>Col4a3<sup>-/-</sup></italic>) mice fed either control diet (0.6% Pi) or a low phosphate diet (0.2% Pi) (new Figure1âfigure supplement 1c, Figure 2âfigure supplement 1f, Figure 4âfigure supplement 1e)</p><disp-quote content-type="editor-comment"><p>3. It is not clear where the supplemental Materials and methods are (l. 566, 576, 585â¦.).</p></disp-quote><p>We apologize and this was a mistake from our side. There are no supplemental Materials and methods, and all the information is within the Materials and methods section of the manuscript.</p><disp-quote content-type="editor-comment"><p>4. Histology of muscle sections seems to be quite different between groups (For example Figure 3E). How were these sections selected?</p></disp-quote><p>Between groups, all gastrocnemius sections were selected at random. Unfortunately, these alluded differences are a result from variations during the paraffin embedding process, which were performed by IDEXX Laboratories. Although embedding variations are noticeable, we think that the pathological differences in myofibers are apparent between groups.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>This manuscript focuses on the impact of high phosphate on skeletal muscle injury and beyond. Although there are gaps, this manuscript would likely to form the basis for further in-depth studies.</p><p>This manuscript is technically sound and addresses an important issue of the direct effect of excessive phosphate in inducing inflammation. The authors also tried to connect the high phosphate and skeletal muscle wasting or anemia to give relevance to chronic kidney disease. The authors also ruled out the involvement of FGF23-FGFR4 in iron deficiency by providing convincing evidence of mouse genetics.</p></disp-quote><p>We thank the Reviewer for the positive evaluation of our main findings. As pointed out, we address the effects of excessive phosphate on regulators of iron metabolism, iron status and skeletal muscle function. First, utilizing mice which harbor global FGFR4 deletion and exposing them to an adenine-rich diet to induce CKD, we show ablating FGF23-FGFR4 signaling does not protect mice from these CKD-associated complications. Supporting this observation, utilizing an established genetic model of progressive CKD, we subject Alport mice to a low phosphate diet as treatment. These observations provide evidence that restricting dietary phosphate leads to a ~ 5 to 10 mg/dL reduction in systemic phosphate levels in comparison to Alport mice on control diet (0.6% phosphate), and alleviates the degree of inflammation, anemia and skeletal muscle dysfunction.</p><disp-quote content-type="editor-comment"><p>The results are of interest and the readership will benefit from the following modifications/ clarifications:</p><p>The reviewer realizes that the heart is not the focus of this study, considering the authors have shown the involvement of FGF23-FGFR4 signaling in cardiac hypertrophy; commenting on the FGF23-FGFR4-independent effects of high phosphate on cardiac structure or function would be useful to know. In other words, do the high phosphate has a differential impact on cardiac vs. skeletal muscle?</p></disp-quote><p>The Reviewer raises an interesting point. Current direct effects of phosphate on the myocardium are not known, and in our opinion, is also difficult to study since it would require animal models with heart-specific loss-of-function approaches for phosphate uptake. This would be challenging since (a) phosphate uptake in the heart might be mediated by more than one transporter, and (b) the complete blockade of phosphate uptake into cardiac cells would be most likely detrimental as all cells depend on constant phosphate uptake for various house-keeping functions, especially myocytes which demand a lot of energy. Cell culture studies suggest that phosphate might affect cardiac cells directly, including the induction of hypertrophic growth of cardiac myocytes (PMID: 25326585; 25999956), but in vivo proof is still missing. We have previously shown that the deletion or blockade of FGFR4 in animal models with high phosphate diet and normal kidney function as well as in animal models with CKD, protects the heart from hypertrophy (PMID:Â 26437603, 28512310). These findings suggest that FGF23/FGFR4, and not phosphate, is the main driver of cardiac hypertrophy in the context of hyperphosphatemia. It is also possible that FGFR4 acts as phosphate receptor (it has been recently shown that <italic>FGFR1</italic> can sense phosphate in bone cells; PMID: 31097591), but we believe that FGF23 is the main ligand for FGFR4.</p><disp-quote content-type="editor-comment"><p>For a high phosphate-induced downstream signaling cascade (Figure 6), the authors should consider explaining their results in the context of the global cytotoxic signaling cascade generated following excessive phosphate exposure (PMID: 32892444).</p></disp-quote><p>We appreciate this suggestion. We added additional information and citations to the Discussion section.</p><disp-quote content-type="editor-comment"><p>It would be nice to know how phosphate activates Pit1 and Pit2?</p></disp-quote><p>This is an important question. PiT<sub>1/2</sub> can act as sensors as well as transporters for phosphate, as shown in other cell types. Other investigators currently focus on this topic and try to determine if PiT<sub>1/2</sub> can bind phosphate which induces structural alterations that lead to changes in signal transduction and/or mediate phosphate uptake so that intracellular sensors detect phosphate and alter signaling events. Studies in this area are still early and mainly done with overexpressed recombinant proteins. We have also started to look into these mechanistic details, but these studies are still early and we believe this is also beyond the scope of the current manuscript.</p><disp-quote content-type="editor-comment"><p>The part of the Discussion section is the repetition of the result section, and the authors should consider minimizing the overlap.</p></disp-quote><p>We appreciate this suggestion. In order to accommodate readers who might only read specific sections of the manuscript, such as the discussion instead of the results, we would prefer to retain the level of detail in our Discussion section. Additionally, this same level of detail could assist readers who might reside in other research fields, that only read the discussion. We believe this brief overlap combined with its interpretations will have a more significant impact on the broad implications for these specific readers.</p></body></sub-article></article>